Patent Grant
10112048
Described herein are devices and methods of use thereof for treating dry eye or tiredness of the eye. The methods generally include applying spatially and/or temporally patterned stimulation to one or more anatomical structures located in an ocular or nasal region. The electrical stimulation may elicit a reflex that activates the lacrimal gland or may directly activate the lacrimal gland or nerves innervating the lacrimal gland to produce tears.
Dry Eye Disease (“DED”) is a condition that affects millions of people worldwide. More than 40 million people in North America have some form of dry eye, and many millions more suffer worldwide. DED results from the disruption of the natural tear film on the surface of the eye, and can result in ocular discomfort, visual disturbance, and a reduction in vision-related quality of life. Activities of daily living such as driving, computer use, housework, and reading have also been shown to be negatively impacted by DED. Patients with severe cases of DED are at risk for serious ocular health deficiencies such as corneal ulceration and can experience a quality of life deficiency comparable to that of moderate-severe angina.
DED is progressive in nature, and generally results from insufficient tear coverage on the surface of the eye. This poor tear coverage prevents healthy gas exchange and nutrient transport for the ocular surface, promotes cellular desiccation, and creates a poor refractive surface for vision. Poor tear coverage typically results from: 1) insufficient aqueous tear production from the lacrimal glands (e.g., secondary to post-menopausal hormonal deficiency, autoimmune disease, LASIK surgery, etc.), and/or 2) excessive evaporation of aqueous tear resulting from dysfunction of the meibomian glands. In turn, low tear volume causes a hyperosmolar environment that induces inflammation of the ocular surface. This inflammatory response induces apoptosis of surface cells, which in turn prevents proper distribution of the tear film on the ocular surface so that any given tear volume is rendered less effective. A vicious cycle is initiated where more inflammation can ensue and cause further surface cell damage, etc. Additionally, the neural control loop, which controls reflex tear activation, is disrupted because the sensory neurons in the surface of the eye are damaged. As a result, fewer tears are secreted and a second vicious cycle develops that results in further progression of the disease (fewer tears cause nerve cell loss, which results in fewer tears, etc.).
There is a wide spectrum of treatments for DED, however, these treatments do not provide adequate treatment of the condition. Treatment options include: artificial tear substitutes, ointments, gels, warm compresses, environmental modification, topical cyclosporine, omega-3 fatty acid supplements, punctal plugs, and moisture chamber goggles. Patients with severe disease may further be treated with punctal cautery, systemic cholinergic agonists, systemic anti-inflammatory agents, mucolytic agents, autologous serum tears, PROSE scleral contact lenses, and tarsorrhaphy. Despite these treatment options, DED continues to be considered one of the most poorly treated diseases in ophthalmology. Accordingly, it would be desirable to have a more effective treatment for dry eye.
Described here are methods for treating one or more conditions (such as dry eye, tired eyes, reducing discomfort from wearing contact lenses, etc.) by providing electrical stimulation to an anatomical structure located in an ocular region or a nasal region. Exemplary anatomical structures include nerves, muscles, mucosal tissues, cutaneous sensory structures such as Parcian corpuscles, Merkel cells, etc., within these regions. The electrical stimulation, when delivered to certain targets as described herein, is generally capable of initiating a reflex circuit that activates the lacrimal gland to produce tears. The reflex circuit may include stimulation of a nerve directly or a cutaneous sensory cell that in turn activates a nerve which then produces either sensory input to the brain, or motor input to a nerve that activates a muscle near, e.g., the eye, which in turn provides sensory input to the brain and initiation of the reflex to activate the lacrimal gland. The electrical stimulation may additionally or alternatively be capable, when delivered to other certain targets as described herein, of directly driving efferent fibers innervating the lacrimal gland to produce tears.
More specifically, methods of generating lacrimation (tear production) by spatially controlling the delivery of electrical stimuli and/or by modifying parameters of electrical waveforms to generate afferent or efferent input are described. These methods generally direct current flow through particular pathways and/or modify the current pathways over time. The methods may also optimize waveforms for a sensed paresthesia, e.g., a sensation of tickle, twitch, and/or vibration in the eyelid and/or vicinity of the eyelid, eyebrow, as well as the temporal and frontal area of the head. Experimentation by the inventors has found that these sensations are strongly associated with lacrimation.
Using the stimuli disclosed herein, it is believed that sensory nerves are activated to send input to the brain to produce lacrimation. Additionally or alternatively, the stimuli may activate motor nerves that cause muscles in the vicinity of the orbit, the nose, the mouth, and/or the frontal or temporal face to vibrate in order to generate the sensation of tingle or twitch or vibration as the effect, which initiates the reflex pathway and thereby leads to lacrimation.
Implantable or hand-held devices may be employed when applying the electrical stimulation. In some handheld variations, the devices may comprise a stimulator body and a stimulator probe. The stimulator probe may be releasably connected to the stimulator body, and in some instances, the stimulator body is reusable and the stimulator probe is disposable. In some variations, the device further comprises a user interface. The user interface may comprise one or more operating mechanisms to adjust one or more parameters of the stimulus. Additionally or alternatively, the user interface may comprise one or more feedback elements.
In handheld variations comprising a stimulator probe, the stimulator probe may comprise one or more nasal insertion prongs, and the stimulator body may comprise a control subsystem to control a stimulus to be delivered to the patient via the stimulator probe. In some of these variations, the stimulator probe comprises a single nasal insertion prong, while in other variations the stimulator probe comprises at least two nasal insertion prongs. The stimulator probe may comprise at least one electrode, and may comprise a plurality of electrodes. The electrode may comprise a hydrogel, or in other variations, the electrode comprises one or more of platinum, platinum-iridium, gold, or stainless steel. Some variations of device may comprise return contacts not located on a nasal insertion prong, such as return contacts on the stimulator body or the stimulator probe.
The electrical stimulation applied to the anatomical structures generally includes a plurality of waveform parameters that define a waveform. Delivery of the electrical stimulus may help to treat DED by inducing an increase in lacrimation, or modifying the components of lacrimated tears, and may generate a paresthesia sensed by a patient. These waveforms may be capable of increasing tear output as well as patient comfort during and/or after application of the stimulation. In some variations, the stimulus is a biphasic pulse waveform, which may but need not be symmetrical. The frequency of the biphasic pulse waveform may in some variations be between 30 Hz and 80 Hz.
In other variations, the devices may include an implantable microstimulator and an external controller. Exemplary implantable devices that may be used to apply the electrical stimulation described herein are disclosed in U.S. patent application Ser. No. 13/441,806, filed Apr. 6, 2012, and titled “Stimulation Devices and Methods,” which is hereby incorporated by reference in its entirety. Exemplary hand-held devices, as well as additional exemplary implantable devices, that may be used to apply the electrical stimulation described herein are disclosed in U.S. patent application Ser. No. 14/256,915, filed Apr. 18, 2014, and titled “Nasal Stimulation Devices and Methods,” which is hereby incorporated by reference in its entirety.
In general, the methods disclosed herein include applying electrical stimulation to an anatomical structure in an ocular region or a nasal region to activate the lacrimal gland, where the electrical stimulation is defined by a plurality of waveform parameters, and increasing tear production using the electrical stimulation. In some instances, the methods may comprise spatially controlling the stimulus delivery to target particular anatomical structure(s) and/or to modify the current pathways over time. The method may further include confirming activation of the lacrimal gland by evaluating a paresthesia sensed in the ocular region or the nasal region.
The anatomical structure that is stimulated may be a nerve, cutaneous sensory cells (Parcian corpuscles, Merkel cells etc.), muscle, or tissue such as mucosa or sub-mucosa, in the ocular region or nasal region. For example, the anatomical structure may be the nasociliary nerve, the anterior or posterior ethmoid nerve, or the infra-trochlear nerve. In some variations, the anatomical structure is a muscle in the ocular region or the nasal region. In some variations, the anatomical structure comprises a mucosal or sub-mucosal surface in the ocular region or the nasal region. In some instances, the anatomical structure may be cutaneous sensory cells in the nasal or ocular glabrous skin, which naturally sense mechanical input such as pressure, vibration, tingle, temperature, or pain.
As further described herein, the flow of current for stimulation may be spatially controlled. Current may be driven between particular contacts and thus through particular pathways through tissue, and may be driven via different pathways through tissue over time to spatially pattern the stimulus. Current steering and/or temporal patterning of waveform parameters may be optimized for a particular patient to activate the lacrimal gland to produce tears and elicit a paresthesia in that patient. Current steering and/or temporal patterning, where at least one of the waveform parameters is modulated over time, may also be determined based on other factors such as clinical markers, including but not limited to growth factor levels and/or osmolarity.
The plurality of waveform parameters that define the stimulation waveforms may be selected from the group consisting of on/off duration, frequency, pulse width, amplitude, and shape. Other suitable waveform parameters may also be used. For example, charge injection, which can be calculated by multiplying amplitude and pulse width, may be used as a waveform parameter. In some variations, the plurality of waveform parameters are selected from the group consisting of on/off duration, frequency, pulse width, amplitude, and shape. In some of these variations, the on/off duration ranges from about 0.1 to 5.0 seconds on, and about 0.1 to 5.0 seconds off. In some of these variations, the on/off duration is 1.0 second on, and 1.0 second off. In some of these variations, the on/off duration is 5.0 seconds on, and 5.0 seconds off. In some of these variations, the frequency ranges from about 10 to 200 Hz. In some of these variations, the frequency ranges from about 30 to 150 Hz. In some of these variations, the frequency ranges from about 50 to 80 Hz. In some variations, the frequency is 30 Hz. In some variations, the frequency is 70 Hz. In some variations, the amplitude ranges from about 0.1 to 10 mA. In some of these variations, the maximum amplitude ranges from about 1 to 3 mA. In some variations, the pulse width and amplitude generate a waveform having a triangular, rectangular, or square shape. In some variations, the electrical stimulation is continuously applied. In other variations, the electrical stimulation has on and off periods.
A particular combination of current steering and/or spatial or temporal patterning may be applied using a stimulator comprising a plurality of combinations stored in memory. Selection of the stored combinations may be random, predetermined, or controlled by a user. In some instances, the stored combinations may be patient-optimized waveforms.
Methods for treating dry eye in a patient in need thereof are described herein. In one variation, the method may comprise contacting nasal mucosa of the patient with an electrode, and delivering current from the electrode through tissue of the patient to a return contact, where the electrode is located on a nasal insertion prong of a stimulator probe of a stimulator, and the return contact is located on a stimulator body of the stimulator, and the stimulator probe is reversibly attachable to the stimulator body. The method may further comprise delivering current from the electrode through tissue of the patient to a second electrode. The second electrode may be located on the nasal insertion prong. In some instances, the current is delivered simultaneously from the electrode to the return contact and to the second electrode; in others, the current is delivered sequentially from the electrode to the return contact and to the second electrode. The electrode may contact the nasal mucosa in the anterior nasal cavity, and in some instances may contact the nasal mucosa at a location anterior to a middle or inferior turbinate of the nasal cavity.
Also described here are methods for treating a patient having dry eye using a stimulator comprising a stimulator body and a stimulator probe, wherein the stimulator probe comprises a nasal insertion prong comprising a first electrode and a second electrode. The method may comprise inserting the nasal insertion prong into a nostril of the patient, placing the first electrode and the second electrode in contact with nasal mucosa on a first side of a septum of the patient, placing a return contact in contact with tissue of the patient, and delivering an electrical stimulation waveform from the first electrode to the second electrode, and from the first electrode to the return contact. The first and second electrodes may be spaced longitudinally along the length of the nasal insertion prong, or they may be spaced radially around a circumference of the nasal insertion prong. In some variations of the method, no electrodes are placed in contact with nasal mucosa on a second side of the septum of the patient, and delivering the electrical stimulation waveform results in bilateral lacrimation.
Methods for increasing tear production in a patient are also described here. The methods may comprise delivering an electrical stimulus to tissue of a patient using a device comprising at least three electrical contacts, wherein the electrical stimulus takes one or more pathways between the at least three electrical contacts during delivery, and wherein the one or more pathways of the electrical stimulus change over time during delivery. The electrical stimulus may take two pathways between the at least three electrical contacts, such that a first amount of current takes the first pathway and a second amount of current takes the second pathway. In some instances, the ratio of the first amount to the second amount changes over time during delivery. The ratio may in some cases be changed by the patient using a user interface of the device. The device may be implantable, or it may be handheld. Some variations of the device have a single nasal insertion prong, which may comprise one electrode, two electrodes, or more. Some variations of the device comprise a stimulator body comprising an electrical contact configured to deliver current or act as a return contact.
In some variations the methods described herein comprise applying patterned electrical stimulation to an anatomical structure in an ocular region or a nasal region to activate the lacrimal gland, and increasing tear production using the patterned electrical stimulation, wherein the patterned electrical stimulation comprises a biphasic waveform having cathodic and anodic pulse pairs. In some variations, a subset of the pulse pairs have a leading cathodic pulse and a subset of the pulse pairs have a leading anodic pulse. In some variations, each pulse has a duration and amplitude, wherein the ratio of duration to amplitude for each pulse is variable over time. In some variations, the biphasic waveform is charge balanced. In some of these variations, the ratio of duration to amplitude for the cathodic pulse varies over time according to a function having a phase of exponential increase and a phase of exponential decrease. In some of these variations, the ratio of duration to amplitude for the cathodic pulse varies over time according to a sawtooth function. In some of these variations, the ratio of duration to amplitude for the cathodic pulse varies over time according to a sinusoidal function.
In some variations the methods described herein comprise implanting a stimulation device in an ocular region or a nasal region of a subject to activate the lacrimal gland, applying patterned electrical stimulation from the stimulation device, and increasing tear production using the patterned electrical stimulation, wherein tear production is bilateral. In some variations, the tear production is approximately equal in both eyes of the subject. Some variations of the methods described herein comprise delivering a stimulus to an ocular region or a nasal region of a subject to activate the lacrimal gland, wherein the stimulus is an electrical waveform, and increasing tear production using the patterned electrical stimulation, wherein tear production is bilateral. In some variations, the stimulus is delivered unilaterally.
The frequency, peak-to-peak amplitude, and pulse width of the waveforms may be constant, but in some variations the stimulator may be configured to vary the frequency, amplitude, and/or pulse width of the waveform. This variation may occur according to a predetermined plan, or may be configured to occur randomly within given parameters. For example, in some variations the waveform may be configured such that the peak-to-peak amplitude of the waveform varies over time (e.g., according to a sinusoidal function having a beat frequency, a sawtoothed function, or an exponential function); in some variations the waveform may be configured such that the frequency of the waveform varies over time (e.g., according to a sinusoidal function, a sawtoothed function, or an exponential function); or in some variations the waveform may be configured such that the pulse width of the waveform varies over time (e.g., according to a sinusoidal function, a sawtoothed function, or an exponential function). In some variations, rectangular stimulation pulses of a variable fundamental frequency are employed. In other variations, triangular stimulation pulses may be used and modulated as described for rectangular stimulation pulses.
In some variations, the methods described herein comprise a method for inducing lacrimation. In some variations the method comprises delivering an electrical stimulus to a patient having dry eye, wherein the electrical stimulus is delivered from a handheld stimulator, and wherein the electrical stimulus comprises a waveform having a pulse width that varies during delivery. In some variations the method comprises delivering an electrical stimulus to a patient having dry eye using a handheld stimulator, wherein the electrical stimulus can be one of a plurality of preset waveforms comprising at least a first preset waveform and a second preset waveform, and changing the electrical stimulus from the first preset waveform to the second preset waveform while delivering the electrical stimulus. The electrical stimulus may be changed from the first preset waveform to the second preset waveform by the patient.
In some variations, the methods described herein comprise providing a device to a patient having dry eye, wherein the device is configured to deliver a plurality of electrical waveforms to an anatomical target in a patient, and instructing the patient to select one or more of the plurality of waveforms based on an amount of sensed paresthesia felt during delivery of the waveform. In some of these variations, the anatomical target may be the nasal mucosa. In some of these variations, the anatomical target may be the anterior ethmoidal nerve. In others of these variations, the anatomical target may be in an ocular region. In some of these variations, at least one of the plurality of waveforms may have a pulse width that varies over time. In some of these variations, the pulse width may vary over time according to an exponential function.
In some variations the methods described herein comprise methods of reducing patient accommodation to electrical stimuli in an ocular, orbital, or nasal region by using patterned waveforms.
In some variations the methods described herein comprise methods of preferentially activating different anatomical structures, comprising implanting a stimulation device, delivering a waveform having a biphasic pulse, and activating a different anatomical structure by modifying the waveform. In some variations, the waveform is modified by adjusting an amplitude of the biphasic pulse. In some variations, the waveform is modified by adjusting the order of a cathodic pulse and an anodic pulse of the biphasic pulse.
Devices for delivering an electrical stimulus to nasal mucosa of a patient are also described here. A device may comprise a stimulator probe comprising a nasal insertion prong, wherein a distal portion of the nasal insertion prong comprises first and second electrodes. The first electrode may be configured to deliver current. The device may also comprise a return contact located on the stimulator probe at the base of the nasal insertion prong, and may also comprise a user interface configured to allow the patient to adjust an amount of current delivered between the first and second electrodes and between the first electrode and the return contact. The first electrode, second electrode, and/or return contact may comprise a hydrogel. In some variations, the return contact has an annular shape. The return contact may be configured to contact tissue at or near a nostril.
A device for delivering an electrical stimulus to nasal mucosa of a patient having dry eye may also comprise a first nasal insertion prong, a second nasal insertion prong, and a user interface. The first nasal insertion prong may be configured to be inserted into a first nostril and may comprise a first electrode. The second nasal insertion prong may be configured to be inserted into a second nostril, and may comprise a second electrode. The device may be configured to deliver a biphasic charge-balanced pulsed waveform, where the user interface is configured to allow the patient to adjust an amplitude:duration aspect ratio of the waveform.
Systems for generating and applying the electrical stimulation waveforms are further disclosed herein. The systems may generally include one or more electrodes and a controller, wherein the controller comprises a programmable memory configured to store a plurality of patterned stimulation waveforms. The stimulation waveforms may or may not be associated with a sensed paresthesia. The controller may also be configured to execute a program that cycles through a plurality of stimulus options. A user interface may be included and configured in a manner that allows the patient to select one or more of the stored plurality of stimuli.
In some variations, the stimulators are configured for implantation in an ocular region or a nasal region. In some of these variations, the stimulators are configured for placement on a mucosal surface or within sub-mucosal tissue. The stimulators, which may for example comprise one, two, three, or more active electrodes, may also be configured for placement within a nasal cavity or a sinus cavity. In other variations, the controller is configured for placement external to the ocular region or the nasal region. In some variations, the electrical stimulation is applied by an electrode disposed within a nasal cavity or a sinus cavity. In some variations, the patterned electrical stimulation is applied by an electrode implanted near the lacrimal gland. In some of variations, the systems are configured for activating cutaneous sensors or nerve fibers innervating cutaneous sensors in the mucosal surface or within sub-mucosal tissue. In some variations, the systems are configured for activating cutaneous sensors or nerve fibers innervating cutaneous sensors in tissue such as skin and muscles of the ocular region, the forehead, or the temple area of the head.
In some variations, the patterned electrical stimulation is applied by a stimulator comprising a plurality of patterned stimulation waveforms stored in memory. In some of these variations, the applied patterned stimulation is randomly selected from the plurality of stored patterned stimulation waveforms. In some of these variations, the plurality of stored patterned stimulation waveforms are patient-optimized waveforms. In some variations, the applied patterned stimulation is stored in memory as a patient-optimized waveform.
In some variations the systems described herein comprise one or more stimulation electrodes and a controller, wherein the controller comprises a programmable memory configured to store a plurality of patterned stimulation waveforms associated with a sensed paresthesia. In some variations, the one or more stimulation electrodes are configured for implantation in an ocular region or a nasal region. In some of these variations, the controller is configured for placement external to the ocular region or the nasal region. In some variations, the one or more stimulation electrodes are configured for placement on a mucosal surface or within sub-mucosal tissue. In some variations, the one or more stimulation electrodes are configured for placement within a nasal cavity or a sinus cavity.
In some variations, the programmable memory is capable of storing up to 10 patterned stimulation waveforms. In some variations the system further comprises a user interface for selecting one or more of the stored plurality of patterned waveforms. In some variations, the controller is configured to execute a program that cycles through a plurality of waveform parameter options.
In some variations, the devices described herein comprise a handheld stimulator comprising a stimulator body comprising a user interface, and a stimulator probe comprising a nasal insertion prong comprising an electrode. The stimulator may be configured to deliver a plurality of electrical waveforms, and the user interface may be configured for selection of one of the plurality of electrical waveforms. Each of the waveforms may have at least one of a pulse shape, maximum amplitude, pulse width, or frequency that is modulated over time. In some of these variations, each of the waveforms has at least two of a pulse shape, maximum amplitude, pulse width, or frequency that is modulated over time. In some variations, each of the waveforms has a pulse shape that is modulated over time. In some variations, the waveform comprises a first period comprising a two-phase current-controlled waveform, and a second period comprising a current-controlled phase followed by a voltage-controlled phase.
Described herein are devices, systems, and methods for treating one or more conditions (such as dry eye, tired eyes, ocular discomfort from wearing contact lenses, etc.) by providing electrical stimulation to an anatomical structure located in an ocular region or a nasal region. Specifically, the methods disclosed herein generally include applying electrical stimulation to an anatomical structure in an ocular region or a nasal region to activate the lacrimal gland, where the electrical stimulation is defined by a plurality of waveform parameters. The electrical stimulation may result in effects such as increased tear production during or after delivery of the stimulus.
In general, the methods disclosed herein include electrically stimulating nerves, muscles (thus indirectly nerves via muscle spindles and golgi-tendon receptors providing sensory information back to the central nervous system), and/or glands in the orbit of the eye or the nasal mucosa and sub-mucosa. With that approach, neural tissue may be activated in some manner. For example, referring to
Exemplary Stimulators
The stimulation waveforms described herein may be delivered via implanted or non-implanted (e.g., handheld) stimulators.
Exemplary Implantable Microstimulators
When the stimulation waveforms described herein are applied using an implantable stimulator, the stimulator may comprise a microstimulator comprising a housing and a corresponding and complementary flexible extension connected to the housing, forming a unitary microstimulator. An example is shown in
The extension 204 may be formed from a flexible material such as silicone, and may comprise a first electrode 206, a second electrode 208, and a coil 210. While shown as having two electrodes, implantable stimulators may have fewer (e.g., one) or more (e.g., three, four, five, six, or more) electrodes. When the implantable stimulator comprises a plurality of electrodes, the current pathways through tissue may be controlled by delivering the current to/from various electrodes, which may be varied over time. In some variations, the extension 204 may be a molded component, such as molded silicone. The extension may have a corresponding and complementary shape to the housing, such that the extension and housing together have a unitary shape, as shown in
The electrodes 206 and 208 and coil 210 may be connected to the microstimulator circuitry via one or more feedthroughs. For example,
When the stimulator is an implantable microstimulator, the system may further comprise a controller, which may communicate with the microstimulator to transmit and/or receive power, information, or the like. For example, in variations in which a stimulation system comprises a microstimulator having a passive stimulation circuit (or a stimulation circuit that does not otherwise include a battery or internal power supply), the controller signal may power the stimulator via the output signal of the controller. The controller may communicate with the microstimulator wirelessly and/or via a wired connection. The controller may be configured for implantation within the body, or may be configured to remain external to the body. The controller may be disposable, may be reusable, or may be partially reusable. In some instances, the controller may be rechargeable.
The length and width of the microstimulator may be selected to permit placement of a portion of the microstimulator on, partially within or about the lacrimal gland, or adjacent to a desired tissue, such as the lacrimal gland or a nerve desired to be stimulated, such as but not limited to the nasociliary nerve or anterior ethmoidal nerve. Some of these implantation locations are described in more detail in U.S. patent application Ser. No. 13/441,806, which was previously incorporated by reference in its entirety; in U.S. patent application Ser. No. 14/256,915, which was previously incorporated by reference in its entirety; and in U.S. patent application Ser. No. 14/207,072, filed Mar. 12, 2014, and titled “Implant Delivery Devices, Systems, and Methods,” which is hereby incorporated by reference in its entirety.
The microstimulator may be injectable into a patient using a delivery system. The delivery system may comprise an insertion device (such as conduit, a shaft to which the microstimulator is removably attachable, or the like) and/or a dissection tool. In some variations, the insertion device is a 12 or larger gauge needle. In other variations, the insertion device comprises a cannula. In some variations, the insertion device may comprise a piston assembly, which in some variations may be spring-powered. The microstimulator may be loaded into the insertion device, and the insertion device may be inserted into an insertion pathway. In some variations in which the microstimulator is implanted into an ocular region, using an anatomical landmark at the corner of the eye, a delivery device (e.g., a needle) may be positioned in proximity to the lacrimal gland, and the microstimulator may be deployed using the delivery device. Anatomical landmarks include, but are not limited to, the lateral canthis, an eyelid margin, a palpebral lobe of the lacrimal gland, the orbital rim, a bony protuberance on the superior-lateral aspect of the orbit, the vascular bed, or the like. In some variations, a microstimulator may be implanted by lifting the eyelid, forming an insertion pathway through the conjunctiva under the eyelid, and advancing the microstimulator into the insertion pathway. The insertion pathway may be formed using a dissection tool. In some variations, the insertion pathway may be formed using a dissection element of an insertion tool. In some variations, the insertion pathway may be formed between the periosteum and the orbital bone. In other variations, the insertion pathway may be formed between the periosteum and the lacrimal gland. The microstimulator may have one or more features to facilitate minimally invasive retrieval. U.S. patent application Ser. No. 14/207,072, which was previously incorporated by reference in its entirely, describes other variations of insertion devices that may be used to implant microstimulators described herein.
Exemplary Handheld Stimulators
The stimulator described here may also be handheld. The handheld stimulators may comprise a stimulator body and a stimulator probe. The stimulator probe may comprise at least one nasal insertion prong configured to be inserted into a nostril of a subject. The stimulator body may be configured to generate a stimulus, which may be delivered to the subject via the nasal insertion prong. The stimulator body may comprise a control subsystem and a power source, which together may generate and control the stimulus.
One variation of a handheld stimulator is shown in
The stimulator body may comprise a user interface comprising one or more operating mechanisms to adjust one or more parameters of the stimulus, as described in more detail below. The operating mechanisms may provide information to the control subsystem, which may comprise a processor, memory, and/or stimulation subsystem. In some variations, the operating mechanisms may comprise first and second buttons, as illustrated for example in
For each handheld stimulator described herein, in some variations the stimulator body and stimulator probe may be reversibly attachable. Some or all of the stimulator may be disposable, and some or all of the stimulator may be reusable. For example, in variations where the stimulator probe is releasably connected to the stimulator body, the stimulator body may be reusable, and the stimulator probe may be disposable and periodically replaced. In some of these variations, the device comprises a disabling mechanism that prevents stimulus delivery to the subject when the stimulator probe is reconnected to the stimulator body after being disconnected from the stimulator body. Additionally or alternatively, the device may comprise a lockout mechanism that prevents the stimulator probe from being reconnected to the stimulator body after being disconnected from the stimulator body. In some variations, the device further comprises a detachable protective cap. The stimulators described herein may have additional features as described in more detail in U.S. patent application Ser. No. 14/256,915, which was previously incorporated by reference in its entirety.
For each handheld stimulator described herein, the stimulator probe may comprise at least one nasal insertion prong. In the handheld stimulator variation shown in
In some variations, the distal portion may have a diameter (or greatest cross-sectional dimension) that is larger than the diameter (or greatest cross-sectional dimension) of the elongate portion of the prong proximal to the distal portion. This may allow a portion of the distal portion (e.g., one or more electrodes, described below) to be brought into contact with a subject's tissue, while the elongate portion is not in contact with the subject's tissue. For example, the diameter of the nasal insertion prong at the distal portion may in some instances be between about 3 mm and about 7 mm, while the diameter of the elongate portion may be between about 1 mm and about 6 mm proximal to the distal portion. More specifically, in some variations the diameter of the nasal insertion prong may be about 5 mm, and the diameter of the elongate portion may be about 3 mm. The proximal portion of the elongate portion may flare outward (i.e., have an increasing diameter or greatest cross-sectional dimension) toward a base member of the stimulator probe, which may in some variations act as a stop to limit the distance that the nasal insertion prong may be advanced into the nose of a user.
Each nasal insertion prong may comprise at least one electrode. Each electrode may be connected to a lead, which may be directly or indirectly connected to a control subsystem and power source, such that an electrical stimulus may travel from the control subsystem, through the leads, and through the electrodes, as described in more detail in U.S. patent application Ser. No. 14/256,915, which was previously incorporated by reference in its entirety.
An electrode may have any suitable design. For example, an electrode may comprise an arc of a cylindrical surface, may be ellipsoid, spherical, ovoid, or the like. An electrode may have any suitable length, such as between about 1 mm and about 10 mm, between about 3 mm and about 7 mm, about 5 mm, or more than about 10 mm. An electrode may be positioned on any suitable longitudinal portion of a nasal insertion prong, and for nasal insertion prongs comprising a plurality of electrodes, may be spaced along the nasal insertion prong. The position of the electrode along the prong may at least partially determine the placement of the electrode relative to tissue when the stimulator probe is advanced into the nose. In some variations, an electrode may be located at an intermediate position along a prong. The electrode may be located any suitable distance from the distal tip of the prong, such as between about 0.1 mm and about 4 mm, about 4 mm and about 8 mm, or more than 8 mm from the distal dip of the prong (e.g., 1 cm from the distal tip). In some variations, an electrode may be located about 2.5 mm from the distal tip of the prong. In some variations in which an electrode is configured to deliver current, the electrode may be located such that when inserted into the nasal cavity, the electrode is capable of reaching the nasal mucosa or other area desired to be stimulated. In some variations, the distance from the base member of the stimulator probe to the longitudinal center of an electrode configured to deliver current (i.e., the farthest the center of the electrode could be inserted into the nasal cavity) may be between about 25 mm and about 45 mm. In other variations, the distance from the base member of the stimulator probe to the longitudinal center of at least one electrode may be between about 30 mm and about 40 mm. For example, in some variations the distance from the base member of the stimulator probe to the longitudinal center of at least one electrode may be about 32.5 mm. However, it should be appreciated that an electrode may be located at other positions, especially when the electrode is configured to be a return electrode. An electrode may also be connected to a distal end of a nasal insertion prong. Generally, when an electrode is positioned at the distal end of a prong, it may be desirable that the electrode have no edges, or rounded edges, to help minimize the risk of tissue damage during advancement of the electrode into the nose.
In some variations, the electrode comprises a hydrogel, which is described in more detail in U.S. patent application Ser. No. 14/630,471, filed Feb. 24, 2015, and titled “Polymer Formulations for Nasolacrimal Stimulation,” which is hereby incorporated by reference in its entirety. However, it should be appreciated that electrodes described herein may comprise other conductive materials, such as metals (e.g., stainless steel, titanium, tantalum, platinum or platinum-iridium, other alloys thereof, or the like), conductive ceramics (e.g., titanium nitride), liquids, gels, or the like. In some variations, the electrode may comprise one or more materials configured to promote electrical contact between electrodes of the stimulator probe and tissue (i.e., all of an electrode or a portion of the electrode, such as a covering). In some instances, the impedance provided by tissue may be at least partially dependent on the presence or absence of fluid-like materials (e.g., mucous) in the nasal cavity. The material(s) may help to minimize the impact of subject tissue impedance by providing a wet interface between the electrode and tissue, which may act to normalize the impedance experienced by the electrode. This may in turn normalize the output and sensation experienced by the user.
The stimulators described herein may comprise at least one lead configured to electrically connect the electrode(s) to the stimulator body circuitry. A lead may extend at least partially through a nasal insertion prong and may be formed from one or more conductive materials (e.g., stainless steel, titanium, platinum or platinum-iridium, other alloys thereof, or the like), conductive ceramics (e.g., titanium nitride), and may be positioned such that at least a portion of the lead contacts the electrode to provide a conduction pathway between the lead and the electrode. In some variations, a lead may comprise a spring, but it should be appreciated that a lead may also comprise a conductive loop, a post, or the like.
In the exemplary handheld stimulator 400 of
While stimulator 400 is shown having two nasal insertion prongs, each comprising a single electrode, in other variations stimulators may comprise a single nasal insertion prong, and/or may comprise a plurality of electrodes on a nasal insertion prong. In some variations comprising a plurality of electrodes on a nasal insertion prong, the electrodes may be spaced longitudinally along the length of the nasal insertion prong, such that they are configured to contact nasal tissue at differing depths within the anterior nasal cavity when inserted into a nostril.
While
In other variations, more than one electrode may be located at the same longitudinal location along the length of the nasal insertion prong. In these variations, the electrodes may be at different locations around the circumference of a nasal insertion prong, i.e., spaced radially around the nasal insertion prong, such that they are configured to contact nasal tissue at different locations at the same depth within the anterior nasal cavity when the nasal insertion prong is inserted into a nostril. For example, when placed into a nostril, an electrode may face toward the front of the nose and another electrode may face toward the septum. In some instances, each electrode may comprise a partial cylinder (e.g., an arc of between about 10 degrees and 180 degrees).
In yet other variations, the electrodes may be spaced both longitudinally along the length of the nasal insertion prong and radially around the circumference of the nasal insertion prong.
It should be appreciated that although the examples described above comprise one, two, or three electrodes on the nasal insertion prongs, nasal insertion prongs may have more (e.g., four, five, six, or more) electrodes, which may be spaced longitudinally along and/or radially around a nasal insertion prong in any suitable arrangement. In some instances, each electrode may have a separate lead, while in others, one or more electrodes may have electrically connected leads (i.e., may be at the same potential).
Additionally or alternatively, some variations of handheld stimulators may comprise a return contact not located on a nasal insertion prong, which may provide an alternative or additional current pathway. For example, a handheld stimulator may comprise a return contact located on the base member of a stimulator probe or on a stimulator body. The return contact may be configured to be in contact with various anatomical locations, such as but not limited to a hand or an area of tissue near the opening of the nostril, the columella, the philtrum, or the upper lip. Further, it should be appreciate that in the configurations described herein, the return contacts may instead be configured to deliver current.
For example,
The return contacts in
In other variations, a return contact may be located on the base member of a stimulator probe, near the base of a nasal insertion prong. For example,
In yet other variations, a return contact may be located on the base member of a stimulator probe, away from the proximal end of a nasal insertion prong. For example,
In the variation shown in
Spatial Control
The electrodes and return contacts described herein may allow stimulus delivery by the stimulators to be spatially controlled. That is, current steering may be achieved by driving current particular pathways between the electrodes or return contacts, and in some instances, the pathway(s) of current flow through tissue may change over time to achieve spatial patterning. The current being delivered by or to each electrode may in some instances be individually controlled in order to achieve these effects. For example, the same or different waveforms, or no waveform, may be delivered by each of the electrodes at any given time, and the stimulus delivery by each of the electrodes may vary over time. Current steering may allow both the current pathways and the quantity of current along each pathway to be controlled. Current steering may enable particular areas of tissue to be targeted by the stimuli, and spatial patterning may affect a subject's perception of the stimulus and may reduce accommodation. Spatial patterning may provide neural activation to varying tissue over time (e.g., to varying sets of nerve branches, such as of the anterior ethmoidal nerve within the nasal mucosa). In some instances, for example, this could be interpreted as similar to a physical movement of a system having a single fixed current pathway, thereby reducing the need for a user to move the electrode within the nose to activate varying sets of neural fibers.
In some variations, exemplary anatomical targets may include nerves, muscles, mucosal or sub-mucosal tissues (e.g., nasal or sinus mucosa or sub-mucosa), sensory cells in the glaborous and hairy skin, glands, or other structures of a patient involved in the process of lacrimation or glandular vasodilation that may be electrically stimulated. For example, the anatomical structures may include, but are not limited to, a lacrimal gland, one or more meibomian glands, lacrimal ducts, cutaneous receptors (mechanoreceptors, Meissner's corpuscles, neurotendinous spindles, golgi tendon organs, Ruffini's corpuscles, Stretch Receptors, Ruffini corpuscle end-organs, Pacinian corpuscle end-organs, hair follicle receptors, free nerve endings, thermoreceptors, bulboid or Krause corpuscles, nociceptors), parasympathetic nerves, fibers and neurites, sympathetic nerves, fibers and neurites, rami lacrimales, the lacrimal nerve, perivascular nerves of lacrimal artery and branches thereof, nerve fibers innervating the meibomian glands, myoepithelial cells of the lacrimal gland, acinar cells of the lacrimal gland, or ductal cells of the lacrimal gland. In yet a further variation, the anatomical structure is the infra-trochlear nerve. In other variations, the anatomical structure is a cutaneous receptor responsible for sensing changes in force or temperature over time or a set of cutaneous receptors in an area of the skin reporting changes in force applied to the skin directly or indirectly by moving hair growing in the skin, or the nerves innervating the cutaneous receptors reporting changes in force applied to the skin or hair in the skin, or temperature changes in the skin including the mucosa, the sub-mucosa in the nose, or the conjunctiva in the eye.
In some instances, it may be desirable to deliver the electrical stimuli described herein to one or more nerves that innervate the lacrimal gland tissue. In others, it may be desirable to deliver the electrical stimuli described herein to the nasal mucosa. This may cause lacrimation by activating the nasolacrimal reflex. In some instances, the targeted area may comprise tissue innervated by the anterior ethmoidal branch of the nasociliary nerve. In another variation, the anatomical structure is the posterior ethmoid nerve. In some instances, the targeted area of the nasal mucosa may be superior to the columella. It may in some instances be near the inferior end of the nasal bone (i.e., near the interface between the nasal bone and the upper lateral cartilage). As such, the stimulus may be delivered between about 20 mm and about 35 mm into the nasal cavity of the patient, in some cases via an electrode between about 25 mm and about 35 mm into the nasal cavity of the patient. In other instances, the targeted area may be the columella. It may be desirable that the stimulus be delivered in the anterior portion of the nasal cavity, within the nostrils and anterior to the turbinates, and in some instances, at a location anterior to the middle turbinate, or at a location anterior to the inferior turbinate. The stimulus may be delivered at least partially through tissue of or near the septum, and it may in some instances be desirable to direct stimulus such that a portion is directed toward the front of the nose. This may allow for selective activation of nerves in the front of the septum (e.g., the ophthalmic branch of the trigeminal nerve) while minimizing activation of nerves toward the rear of the nasal septum, which may reduce negative side effects that may occur from stimulation of nerves that innervate the teeth, and which may reduce rhinorrhea. It may also in some instances be desirable to direct the stimulus so as to reduce negative side effects that may occur from stimulation of the olfactory area.
One way to achieve stimulation of one or more of these target areas may be current steering. For example, current may be directed to flow in a pathway such that it is concentrated in areas where a target nerve (e.g., the anterior ethmoidal nerve) is located (e.g., certain portions of the septum) while avoiding stimulating areas that may cause discomfort or unnecessary unpleasant sensations (e.g., portions of the trigeminal nerve that innervate the teeth). By steering current in this way, preferential activation of particular nerves may be achieved with waveforms that might not otherwise be able to achieve preferential activation.
In handheld stimulation devices comprising one or more nasal insertion prongs, for example, current steering may be used to drive current between electrodes on the same prong and, additionally or alternatively, in devices comprising two nasal insertion prongs, between electrodes on different prongs. As described herein, handheld stimulation devices may also comprise one or more return contacts to provide additional possible current pathways. Spatial control may allow both the current pathways and the quantity of current along each pathway to be controlled, and may allow these to be changed over time. By controlling the current pathways, particular tissue areas can be targeted. In some variations, current steering may be used to adjust the location of stimulus delivery to a desired region of tissue without having to move an implanted or temporarily inserted stimulator.
In some cases, the current steering may be accomplished by having isolated circuits with separate current sources for each pathway, wherein each is floating without a common ground. In other cases, the current steering may be accomplished using a single current source based on the impedance values of multiple pathways. Current steering may also in some instances be carried out using a multiplexor, which may be located inside a waveform generator. In other instances it may be carried out using frequency selectivity, for example, by different electrodes being connected to receiver coils having different resonant frequencies, such that small changes in controller frequencies may allow for selective delivery of stimulus by the electrodes.
As one example of spatial control,
Whereas in the examples of
Current may also be steered between one or more electrodes located on a nasal insertion prong and one or more return contacts. Turning back to the handheld nasal stimulator of
As another example,
The paths through which current is steered may be changed over time to spatially pattern the stimulus delivery. That is, for example, during a first time period the current may be driven via a first set of pathway(s), and during a second time period the current may be driven via a second set of pathway(s). This may generate the sensation of a moving stimulus, which may reduce patient accommodation to the stimulus. For example, the handheld nasal stimulator 3000 may be configured to cycle, either in a predetermined fashion, randomly, or under user control, through the current steering patterns shown in
As another example,
By switching between current delivery to be from different electrodes, the current pathway may be changed over time, which may allow stimulation of different tissue areas over time. This may in turn reduce accommodation and/or may allow particular anatomical areas to be targeted. In some instances, it may be desirable to temporarily target particular areas. For example, periodic partial activation of CN-V2 may reduce the sensation of needing to sneeze that may otherwise be perceived during stimulation of the anterior ethmoidal nerve.
Similarly,
In some variations, the current may be steered sequentially via the various pathways. This type of spatial patterning may be achieved in stimulators comprising a single current source used to drive two or more electrodes versus a common ground. This may be implemented using, for example, a multiplexor. The current may also be steered simultaneously via the various pathways. This type of current steering may be achieved in stimulators comprising a plurality of independent, or electrically floating, current sources. In these variations, a multiplexor may also be used to control which electrodes receive current from each source.
While the figures discussed above show the application of current steering to a handheld nasal stimulator, it should be appreciated that current steering may be applied with use of other devices, such as implantable stimulators (e.g., stimulators implanted in ocular or nasal regions) described herein. The ability to target particular areas of tissue without moving the electrode contact points may be particularly useful in the case of implantable stimulators having a fixed position relative to tissue.
When stimulators are configured for spatial patterning of stimulus delivery, the spatial patterning may have any suitable parameters. For example, current delivery may be switched between two or more pathways at a predetermined frequency, such as about every 0.5 seconds, 1 second, 2 seconds, 5 seconds, 10 seconds, or longer. In other variations, a user may be able to switch between two or more pathways using a user interface, such as a user interface described herein. In yet other variations, the pathway may be selected by a clinician for an individual patient. For example, when the stimulator is an implantable stimulator, a clinician may be able to select a pathway after implantation, so that the stimulated tissue can be tailored after implantation without having to adjust the implantation site.
Waveforms
The electrical stimulation waveforms delivered by the stimulators described herein may be tailored for specific treatment regimens and/or specific patients. In variations of stimulators configured to deliver current via two or more pathways, different waveforms may be delivered via each pathway, and the waveform delivered via each pathway may be changed over time. Returning to
As is described in more detail herein, when temporal patterning of electrical stimulation waveforms is employed, waveform parameters such as the shape, the frequency, the amplitude, and the pulse width may be modulated. The frequency, pulse-width, and/or amplitude of the waveform may be modulated linearly, exponentially, as a sawtooth, a sinusoidal form, etc., or they may be modulated randomly. The stimulation can also be interrupted as part of the temporal patterning. That is, the stimulation can be in an on/off condition, e.g., for durations of 1 second on/1 second off, 5 seconds on/5 seconds off, etc. Modulation of the waveform shape (e.g., rectangular vs. triangular vs. exponential) in a rhythmic or non-deterministic, non-rhythmic fashion may also be used. Thus, numerous variations in temporal waveform patterning can be achieved. It should be understood that combinations of these parameter changes over time in a repetitive manner may also be considered temporal patterning. In some instances, random temporal patterning may be employed. Temporal patterning may help to prevent patient habituation to the applied stimulation (i.e., may help to prevent the patient response to the stimulation decreasing during stimulation).
In some instances, it may be desirable to configure the stimulation waveform to minimize side effects. In some instances, it may be desirable to promote stimulation of larger-diameter nerves (e.g., afferent fibers of the trigeminal nerve), which may promote a therapeutic effect, while reducing the stimulation of smaller nerves (e.g., a-delta fibers, c fibers, sympathetic and parasympathetic fibers), which may result in pain, discomfort, or mucus production. Generally, for smaller pulse-widths, the activation threshold for larger-diameter nerves may be lower than the activation threshold for the smaller nerve fibers. Conversely, for larger pulse-widths, the activation threshold for larger-diameter nerves may be higher than the activation threshold for the smaller nerve fibers. Accordingly, in some instances, it may be desirable to select a pulse width that preferably actuates the larger-diameter nerves. In some variations, the pulse width may be between 50 μs and about 1200 μs. As another example, certain waveforms may minimize activation of the branches of the trigeminal nerve (e.g., CN V2) that travel to the teeth. These may include waveforms ranging from 30 μs to 300 μs in pulse width, 10 Hz to 150 Hz in frequency, and 0.1 mA to 5 mA in amplitude.
The stimulation may be delivered periodically at regular or irregular intervals. Stimulation bursts may be delivered periodically at regular or irregular intervals. The stimulation amplitude, pulse width, or frequency may be modified during the course of stimulation. For example, the stimulation amplitude may be ramped from a low amplitude to a higher amplitude over a period of time. In other variations, the stimulation amplitude may be ramped from a high amplitude to a lower amplitude over a period of time. The stimulation pulse width may also be ramped from a low pulse width to a higher pulse width over a period of time. The stimulation pulse width may be ramped from a high pulse width to a lower pulse width over a period of time. The ramp period may be between 1 second and 15 minutes. Alternatively, the ramp period may be between 5 seconds and 30 seconds.
The temporally patterned stimulation waveforms described herein may be used to increase the comfort of the patient and/or may be used to improve the efficacy of the stimulation, and thus, described below are waveform parameters that may be used alone or in combination to increase comfort and/or efficacy.
It should be appreciated that the waveforms described here may be delivered via a multi-polar, such as bipolar, tripolar, quad-polar, or higher-polar configuration or a monopolar configuration with distal return. The waveforms may be a sinusoidal, quasi-sinusoidal, square-wave, sawtooth, ramped, or triangular waveforms, truncated-versions thereof (e.g., where the waveform plateaus when a certain amplitude is reached), or the like, as described in more detail herein.
Shape
In some instances, the waveform shape or modulation thereof may affect the comfort and/or efficacy of the stimulation. When the stimulator (electrode device) is configured to create a pulse-based electrical waveform, the pulses may be any suitable pulses (e.g., a square pulse, a haversine pulse, or the like). The pulses delivered by these waveforms may by biphasic, alternating monophasic, or monophasic, or the like. When a pulse is biphasic, the pulse may include a pair of single phase portions having opposite polarities (e.g., a first phase and a charge-balancing phase having an opposite polarity of the first phase). Each phase of the biphasic pulse may be either voltage-controlled or current-controlled. In some variations, both the first phase and the charge-balancing phase of the biphasic pulse may be current-controlled. In other variations, both the first phase and the charge-balancing phase of the biphasic pulse may be voltage-controlled. In still other variations, the first phase of the biphasic pulse may be current-controlled, and the second phase of the biphasic pulse may be voltage-controlled, or vice-versa. In some instances, a combination of current-controlled bilateral stimulation and voltage-controlled charge balancing may allow for unilateral stimulation, and by modifying the waveform shape, may allow for switching between areas of stimulation, e.g., between nostrils when electrodes are located in each nostril, as described herein.
In some variations in which the waveform comprises a biphasic pulse, it may be desirable to configure the biphasic pulse to be charge-balanced, so that the net charge delivered by the biphasic pulse is approximately zero. In some variations, a biphasic pulse may be symmetric, such that the first phase and the charge-balancing phase have the same pulse width and amplitude. Having a symmetric biphasic pulse may allow the same type of stimulus to be delivered, e.g., to each nasal cavity. The pulses of a first phase may stimulate a first side of the nose (while providing a charge-balancing phase to a second side of the nose), while the pulses of the opposite phase may stimulate the second side of the nose (while providing a charge-balancing phase to the first side of the nose).
In other variations in which the waveform comprises a biphasic pulse, a biphasic pulse may be asymmetric, where the amplitude and/or pulse width of the first pulse may differ from that of the charge-balancing phase. Even if the biphasic pulse is asymmetric, the biphasic pulse may be charge-balanced. For example, the cathodic pulse may have lower amplitude but longer duration than the anodic pulse, or the cathodic pulse may have higher amplitude but shorter duration than the anodic pulse. In both instances, the charge injection (amplitude times duration) may be equal for each pulse, such that the net charge delivered by the biphasic pulse is approximately zero.
The shape of the waveform may be changed to preferentially activate the tissue near an electrode. For example,
In some variations the waveform may transition between two aspect ratios in an abrupt fashion. In other variations the transition may be gradual, where the aspect ratio of the cathodic pulse may increase over time and then decrease over time, while the aspect ratio of the anodic pulse may decrease over time and then increase over time.
In some variations, the polarity is switched back and forth between a pattern in which the cathodic pulse is first and a pattern in which the anodic pulse is first. For example,
Although the patterns having variable amplitude:duration aspect ratios may have uniform charge injection, they may preferentially activate the tissue near one of the two electrodes. That is, when the leading cathodic pulse has a greater amplitude and shorter duration than the anodic pulse, the waveform may preferentially activate tissue near a cathodic electrode; when the leading cathodic pulse has a lesser amplitude and longer duration than the anodic pulse, the waveform may preferentially activate tissue near an anodic electrode. Changing aspect ratios and switching polarities as described herein may increase the lacrimation response and/or change tear composition resulting from stimulation. This may be because switching polarities leads to non-linear addition of the stimuli as perceived by the central nervous system, as well as because switching polarities may reduce a patient's accommodation to the stimuli. Additionally, some stimulators described herein may be configured such that a user may be able to change the aspect ratios of a biphasic waveform in order to change the location or extent of preferential activation, such as by using a user interface. For some patients, adjusting the aspect ratio may result in a perception of a more symmetrical waveform and/or result in a more symmetrically bilateral treatment effect. In some instances, it may be desirable to have an asymmetrical bilateral treatment effect, or a unilateral treatment effect, for example in a patient having more severe dry eye in one eye than the other. In these instances, a patient may use a user interface to adjust the aspect ratio to achieve the desired asymmetrical effect.
Frequency
In order to treat dry eye or otherwise produce a tearing response by stimulating tissue, the stimulators described herein may be configured to generate one of more waveforms at frequencies suitable for stimulating targeted tissue (e.g., a nerve). The frequency may affect the comfort and/or efficacy of the stimulation. Generally, the frequency is preferably between about 0.1 Hz and about 200 Hz. In some of these variations, the frequency is preferably between about 10 Hz and about 200 Hz. In some of these variations, the frequency is preferably between about 30 Hz and about 150 Hz. In others of these variations, the frequency is preferably between about 50 Hz and about 80 Hz. In others of these variations, the frequency is preferably between about 30 Hz and about 60 Hz. In some variations, the frequency may be about 1.5 Hz, about 10.25 Hz, about 70 Hz, about 150 Hz, about 25 Hz, about 27.5 Hz, about 30 Hz, about 32.5 Hz, about 35 Hz, about 37.5 Hz, about 40 Hz, about 42.5 Hz, about 45 Hz, about 47.5 Hz, about 50 Hz, about 52.5 Hz, about 55 Hz, about 57.5 Hz, about 60 Hz, about 62.5 Hz, or about 65 Hz. In some variations, high frequencies, such as those between about 145 Hz and about 155 Hz may be too high for each pulse to stimulate/activate the target tissues. As a result, the stimulation may be interpreted by the patient to have an element of randomness, which in turn may help to reduce patient habituation. The frequencies described herein may be suitable for stimulating the targeted tissue to initiate a reflex circuit that activates the lacrimal gland to produce tears, and/or suitable for directly driving efferent fibers innervating the lacrimal gland. In some instances, the frequency may be chosen for preferential activation of certain anatomical targets, as described herein.
Amplitude
In order to treat dry eye or otherwise produce a tearing response by stimulating tissue, the stimulators described herein may be configured to deliver a current suitable for stimulating targeted tissue (e.g., a nerve). The maximum amplitude or modulation thereof may affect the comfort and/or efficacy of the stimulation. When the stimulus comprises a biphasic pulse and the first phase of the biphasic pulse is current-controlled, the first phase may preferably have an amplitude between about 1.0 mA and about 10 mA. Amplitudes within these ranges may be high enough to stimulate targeted tissue, but sufficiently low as to avoid any significant heating of tissue, ablation of tissue, or the like. In some variations the amplitude may be between about 1.0 mA and about 5.0 mA. In other variations, the first phase may have an amplitude of about 0.1 mA, about 0.2 mA, about 0.3 mA, about 0.4 mA, about 0.5 mA, about 0.6 mA, about 0.7 mA, about 0.8 mA, about 0.9 mA, or about 1.0 mA. In some variations, the amplitude may be variable. For example, the amplitude may vary between about 1.3 mA and about 1.5 mA, about 2.2 mA and about 2.5 mA, about 3.2 mA and about 3.7 mA, about 4.3 mA and about 5.0 mA. When the first phase of a biphasic pulse is voltage-controlled, the first phase may preferably have an amplitude between about 10 mV and about 100 V.
When a stimulator is configured to deliver a pulse-based waveform, in some variations, the amplitude of the pulses may be constant over time. In other variations, the amplitude of the pulses may vary over time. This may reduce patient accommodation. In some variations, the amplitude of pulses may increase (linearly, exponentially, etc.) from a minimum value to a maximum value, drop to the minimum value, and repeat as necessary. In some variations, the amplitude of the pulses may vary according to a sinusoidal profile. In another variation, as illustrated in
In some variations in which the amplitude varies over time, the amplitude may vary at a frequency suitable for reducing patient accommodation or increasing patient comfort such as between about 0.1 Hz and about 5 Hz, between about 1 Hz and about 5 Hz, between about 1 Hz and 2 Hz, between about 2 Hz and 3 Hz, between about 3 Hz and 4 Hz, or about 4 Hz and about 5 Hz. In some variation, the amplitude may vary at a frequency of about 1.0 Hz, about 1.1 Hz, about 1.2 Hz, about 1.3 Hz, about 1.4 Hz, about 1.5 Hz, about 1.6 Hz, about 1.7 Hz, about 1.8 Hz, about 1.9 Hz, about 2.0 Hz, about 2.1 Hz, about 2.2 Hz, about 2.3 Hz, about 2.4 Hz, about 2.5 Hz, about 2.6 Hz, about 2.7 Hz, about 2.8 Hz, about 2.9 Hz, about 3.0 Hz, about 3.1 Hz, about 3.2 Hz, about 3.3 Hz about 3.4 Hz, about 3.5 Hz, about 3.6 Hz, about 3.7 Hz, about 3.8 Hz, about 3.9 Hz, or about 4.0 Hz. In other variations, the stimulation waveform may be a modulated high frequency signal (e.g., sinusoidal), which may be modulated at a beat frequency of the ranges described above. In such variations, the carrier frequency may be between about 100 Hz and about 100 kHz.
Pulse Width
In order to treat dry eye or otherwise produce a tearing response by stimulating tissue, the stimulators described herein may be configured to deliver a waveform in which the first phase may preferably have a pulse width between about 1 μs and about 10 ms. In some of these variations, the pulse width may be between about 10 μs and about 100 μs. In other variations, the pulse width may be between about 100 μs and about 1 ms. In yet other variations, the pulse width may be between about 0 μs and about 300 μs. In yet other variations, the pulse width may be between about 0 μs and 500 μs. As described above, it may be desirable to select a pulse width that preferably actuates larger-diameter nerves. In some variations, the pulse width may be between 50 μs and about 1200 μs. As another example, pulse widths of 30 μs to 300 μs may minimize activation of the branches of the trigeminal nerve (e.g., CN V2) that travel to the teeth.
In some variations, the pulse width may be constant over time. In other variations, the pulse width may vary over time. Pulse width modulation over time may increase the efficacy and/or comfort of the stimulation. In some variations, the pulse width may increase (linearly, exponentially, etc.) from a minimum value to a maximum value, drop to the minimum value, and repeat as necessary. In some variations, the pulse width may vary according to a sinusoidal profile. In another variation, as illustrated in
In some variations, the increase and decrease of pulse width may be defined by a function implemented by the stimulator. For example, the pulse width may be defined by a function such that the pulse width varies exponentially. In one variation, the function defining pulse width may comprise two phases—a first phase during which the pulse width of the leading pulse increases over time, and a second phase during which the pulse width of the leading pulse decreases over time. During the first phase, the pulse width of the leading pulse approaches the maximum pulse width according to an exponential function, where at time t, PW{t} is defined by the equation
where PWmax is the maximum allowed pulse width, PWmin is the minimum allowed pulse width, and τ is a time constant.
Once a predetermined amount of time has elapsed (a multiple of time constant τ), the pulse width modulation may enter the second phase. During the second phase, the pulse width of the leading pulse exponentially decays from its maximum value to a minimum value following the exponential equation
After a predetermined amount of time has elapsed (a multiple of time constant τ), the pulse width modulation may re-enter the first phase, and the cycle may repeat. The pulse width of the secondary (charge balancing) pulse is increased and decreased accordingly to retain charge full balancing. PWmax, PWmin, and τ may have any suitable values to achieve the pulse widths described herein, but in one example the waveform may have a PWmax of 300 μs, PWmin of 0 μs, and τ of ⅕ μs. In other variations, for example, PWmax, may be about 100 μs, about 200 μs, about 300 μs, about 400 μs, or about 500 μs; PWmin may be about 0 μs, about 10 μs, about 50 μs, or about 100 μs; and τ may be about ⅓ μs, about ¼ μs, about ⅕ μs, or about ⅙ μs. An exemplary function defining exponentially increasing and decaying pulse widths is shown in
On/Off Periods
In some instances, the waveforms described herein may be delivered in a continuous fashion, while in other instances, the waveforms may be delivered in a non-continuous fashion having on periods and off periods, which may reduce patient accommodation. Exemplary on/off durations include without limitation, 1 second on/1 second off, 1 second on/2 seconds off, 2 seconds on/1 seconds off, 5 seconds on/5 seconds off, 0.2 seconds on/0.8 seconds off, less than 1 second on/less than 10 seconds off.
Exemplary Waveforms
It should be appreciated any of the above waveform parameters and variations in parameters may be combined to generate a temporally patterned waveform as described herein, and these waveforms may be delivered by any of the stimulators described herein. For example, in variations where the waveform comprises a biphasic pulse, the biphasic pulse may have any suitable frequencies, pulse widths, and amplitudes. The stimulation amplitude, pulse width, and frequency may be the same from pulse to pulse, or may vary over time, as described in more detail herein. Combinations of these parameters may increase the efficacy and/or comfort of stimulation, and in some cases, the efficacy and/or comfort may differ by individual patient, as described in more detail herein. Exemplary waveform parameters categorized by device type are listed below in Table 1.
In variations in which a waveform is an alternating monophasic pulsed waveform, each pulse delivered by the stimulator may have a single phase, and successive pulses may have alternating polarities. Generally, the alternating monophasic pulses are delivered in pairs at a given frequency (such as one or more of the frequencies listed above, such as between 30 Hz and 80 Hz), and may have an inter-pulse interval between the first and second pulse of the pair (e.g., about 100 μs, between 50 μs and 150 μs or the like). Each pulse may be current-controlled or voltage-controlled, and consecutive pulses need not be both current-controlled or both voltage-controlled. In some variations where the pulse waveform is charged-balanced, the waveform may comprise a passive charge-balancing phase after delivery of a pair of monophasic pulses, which may allow the waveform to compensate for charge differences between the pulses.
When a stimulator configured to deliver an electrical stimulation waveform is positioned to place an electrode on either side of the nasal septum, alternating monophasic pulses may promote bilateral stimulation of nasal tissue. The pulses of a first phase may stimulate a first side of the nose (while providing a charge-balancing phase to a second side of the nose), while the pulses of the opposite phase may stimulate the second side of the nose (while providing a charge-balancing phase to the first side of the nose), since nerves may respond differently to anodic and cathodic pulses. The inter-pulse interval may give time for the stimulation provided by a first phase pulse to activate/polarize the target nerves prior to being reversed by an opposite phase pulse.
Stimuli comprising the waveforms described herein may be delivered to these anatomical targets using stimulators such as those described herein according to treatment regimens described in U.S. patent application Ser. No. 13/441,806, which was previously incorporated by reference in its entirety, and in U.S. patent application Ser. No. 14/256,915, which was previously incorporated by reference in its entirety.
Patient-Optimized Waveforms
Experimentation by the inventors has found that in some instances, lacrimation caused by stimulation may be increased by identification of one or more patient-optimized waveforms for a particular patient, where the patient-optimized waveforms may comprise combinations of the waveform parameters described herein. As such, a method for identification of patient-optimized waveforms is desirable. Experimentation by the inventors has also found that sensed paresthesia is strongly associated with lacrimation, and thus patient perceptions of paresthesia may be used in identification of patient-optimized waveforms. An exemplary method for obtaining patient-optimized waveforms in a patient having a microstimulator implanted in an ocular region is illustrated in
As shown there, a waveform may be assessed to determine if it is a patient-optimized waveform by delivering an electrical stimulus comprising the waveform to the patient using a stimulator described herein. The method may comprise first delivering a waveform at the lowest amplitude and/or pulse width and asking the patient for feedback on the sensation as the amplitude and/or pulse width is increased. The method may then comprise assessing whether the patient feels any sensation during delivery of the electrical stimulus. If not, a different waveform may be selected (e.g., having a different combination of parameters, such as frequency, amplitude, pulse width, on/off period, or the temporal modulation of these parameters). The method may further comprise ensuring that the patient is not experiencing discomfort. If the patient is experiencing discomfort, the method may be restarted with a new waveform, or the amplitude and/or the pulse width may be reduced to alleviate discomfort. Similarly, the method may comprise ensuring that the sensation during application of the waveform is comfortable to the patient. The amplitude and/or pulse width may be adjusted to achieve patient comfort. Comfort may be assessed with the patient's eyes both open and closed.
A waveform may be designated as a patient-optimized waveform if the patient perceives the waveform as the most comfortable and/or effective waveform felt that day; and/or if the patient feels his/her eyes getting wet; and/or if the patient perceives paresthesia—more particularly, if both a tickle and a vibration are perceived as moving in the eyelid. If the patient perceives a tickle in the eyelid but no vibration, the amplitude and/or pulse width may be adjusted to achieve increased perception of tickle and/or vibration. If the patient perceives a vibration but not tickle, the amplitude and/or pulse width may be adjusted to achieve an increased sensation of movement of the vibration (e.g., between the eyelid and eyebrow). It may also be desirable that a patient feels a sensation (e.g., tickle or vibration) after delivery of the stimulus ends. In each case of an identified patient-optimized waveform, a lower amplitude and/or pulse width may be tested to determine whether the same sensation can be achieved using a lower amplitude and/or pulse width. In variations of stimulators configured to allow for spatial control of current pathways, patient-optimization may also comprise testing different current pathways or combinations of current pathways.
While the method in
Devices Having a Plurality of Waveforms
Some variations of the stimulators described herein may be configured with a plurality of waveforms, such that a clinician and/or patient may select a desired waveform from the plurality of available waveforms. For example, the stimulator may include a plurality of stimulation waveforms saved on a chip. For example, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 stimulation waveforms may be saved on a chip. In one variation, two to ten stimulation waveforms are saved on a chip. In other variations, two to eight stimulation waveforms, or three to five stimulation waveforms may be saved on the device chip. In some variations, a preferred set of waveforms to be saved on a stimulator may be preselected by a clinician based on initial testing of a variety of stimulation waveforms for a particular patient, such as via the method described above. It may be useful for the saved stimulation waveforms to be those that elicit strong paresthesia in the patient, because experimentation by the inventors has found that sensed paresthesia is more strongly associated with lacrimation, as described herein. In other variations, a stimulator may be preconfigured with a plurality of stimulation waveforms not unique to an individual patient.
In some variations, for every stimulation provided during the day, a different waveform may be randomly selected from the saved plurality of waveforms. By randomly selecting a different waveform each time, the risk of patient developing tolerance to any particular stimulation pattern may be lowered. In another implementation, a multiplexor might be used to provide different combinations of internally saved waveforms to form a “quasi-non-repetitive” waveform when combining pieces from different repetitive waveforms. By multiplexing different waveforms to one combined waveform, habituation to the waveform can potentially be limited further. For stimulators having a plurality of possible current pathways, the same or different waveforms may be delivered via each pathway.
In some variations, a patient may be able to selectively choose between the plurality of stimulation waveforms saved on the stimulator, for example, using a user interface such as a user interface as described herein. In variations having such a user interface, the user interface may comprise one or more operating mechanisms, which may allow the user (i.e., the patient) to control the stimulation waveform. For example, the user interface may comprise one or more structures, such as but not limited to a button, slider, lever, touch pad, knob, or deformable/squeezable portion of the housing, which may allow the user to change the stimulation waveform.
The different waveforms may be configured such that a patient may perceive them as spanning a range of intensities. In variations in which the stimulator is configured to deliver waveforms with different shapes, a patient may be able to change the tissue that is preferentially stimulated by the waveform as described herein by selecting a waveform having a different shape (e.g., switching from a waveform having a cathodic pulse first to a waveform having an anodic pulse first). In some variations, when a patient turns on the stimulator for a second or subsequent treatment period, the stimulator may initially turn on to a waveform selected previously by the patient (e.g., the waveform used during the previous treatment session, the most commonly used waveform during a plurality of treatment sessions, etc.).
For example, in the instance where a handheld nasal stimulator is employed, after the user has placed a portion of the stimulator in contact with the nasal tissue, the user may increase the perceived intensity of the stimulus by changing between the plurality of stimulation waveforms. It may be desirable for the patient to increase the intensity of the stimulus until the stimulus causes preferred paresthesia (e.g., tingling, tickling, prickling) without causing discomfort. As such, the patient may be able to self-determine the proper stimulation intensity and self-adjust the stimulus to a waveform effective to achieve the desired result (e.g., tear production). It may be desirable for the user to increase the intensity of the stimulus slowly in order to minimize discomfort. Some patients might prefer their sensation level to change over the course of time. They might want to start with a strong sensation, followed by a weak sensation. They might prefer to start with a weak sensation (e.g., light tickle) followed by a stronger temporary sensation (e.g., light discomfort for a very short time). Some patients may be able to reduce a sensation of needing to sneeze during stimulation if strong and weak sensations are varied.
In one particular example, a stimulator described herein may be configured to deliver a plurality of different waveforms each having a combination of one or more of shape modulation, maximum amplitude modulation, pulse width modulation, and frequency modulation, as described herein.
One or more of the waveforms may have a pulse shape that is modulated over time. In a variation illustrated in
One or more of the waveforms may have a pulse width that is modulated over time. In one variation, the pulse width of the current-controlled phases may be modulated from 0 μs to 300 μs. The modulation may follow an exponential function that describes the increase and decrease of the pulse width over time, as illustrated in
One or more of the waveforms may have a maximum amplitude that is modulated over time. The amplitude modulation of the current-controlled phases may approximate a triangular shape, a rectangular shape, or any other suitable shape. Exemplary amplitude modulations at various frequencies are illustrated in
The five waveforms of
Setting 1, illustrated in
Setting 2, illustrated in
Setting 3, illustrated in
Setting 4, illustrated in
Setting 5, illustrated in
Through waveforms having these parameter combinations, a large parameter space may be provided on a single device with a simple user interface and a limited number of settings. This may increase the ability of a single device having a limited number of preset waveforms to deliver a waveform that is as effective or nearly as effective for an individual patient as a waveform in which parameters are individually tuned for each patient.
The following examples further illustrate the electrical stimulation patterns and their effects as disclosed herein, and should not be construed in any way as limiting their scope.
Patients having microstimulators implanted in an ocular region were tested with 30 Hz non-patterned stimulation (control) and with on/off patterns (1 second on/1 second off, 2 seconds on/2 seconds off, and 5 seconds on/5 seconds off) at different frequencies (30 Hz, 70 Hz, and 155 Hz). The implanted microstimulators had the features shown in
Patient perception of the stimulus differed between the 30 Hz non-patterned waveform control and temporally patterned waveforms. Specifically, whereas 3 patients receiving the 30 Hz non-patterned waveform felt that their perception of the waveform faded over the stimulation period, when receiving temporally patterned waveforms, no patients reported perception of the waveform fading over the stimulation period. When the stimulus was a 30 Hz, 1 second on/off waveform (“Pattern 1”), 3 patients perceived the waveform as continuous, while 15 perceived the waveform as intermittent. When the stimulus was a 30 Hz, 5 second on/off waveform (“Pattern 2”), all patients perceived the waveform as intermittent. When the stimulus was a 70 Hz, 1 second on/off waveform (“Pattern 3”), 2 patients perceived the waveform as continuous, and 10 perceived the waveform as intermittent. Patients reported that they perceived Pattern 3 as “stronger,” “faster,” and “sharper” than the other waveforms. When the stimulus was a 155 Hz, 1 second on/off waveform (“Pattern 4”), whether patients perceived the waveform as continuous or intermittent was amplitude-dependent, and qualitative perceptions ranged, including reports of the waveform as “weaker,” “strong,” or a “pinch.”
Moreover, patients reported a change in the quality and/or location of paresthesia.
Patient perceptions after cessation of stimulation also differed between the 30 Hz non-patterned waveform and the temporally patterned waveforms. Whereas patients did not perceive paresthesia after cessation of the control, patients reported perceiving paresthesia in the form of a tingling sensation after cessation of Patterns 1, 3, and 4.
Schirmer scores increased with temporally patterned waveforms as compared to the 30 Hz non-patterned waveform control. With Pattern 1, one third of patients had Schirmer scores that increased by 50%. With Pattern 3, three quarters of patients had Schirmer scores that increased by 50-100%. With Pattern 4, three eighths of patients had Schirmer scores that increased by 100% or more.
Some of the temporally patterned waveforms also provided additional advantages. For example, Pattern 1 used less power than the control while also reducing patient accommodation; and Pattern 4 allowed for both nerve stimulation and block.
In patients having a microstimulator implanted in an ocular region, use of temporally patterned waveforms generated an increase in lacrimation as measured by Schirmer's test in comparison to basal tearing (control 1=no electric stimulation) and in comparison to stimulation at 30 Hz (non-patterned) (control 2). The implanted microstimulators had the features shown in
The temporally patterned waveforms were also capable of generating paresthesia in patients in whom paresthesia was not felt during stimulation or who only experienced short-lived paresthesia (e.g., less than 30 seconds, often only less than 10 seconds, of paresthesia felt even though stimulation was supplied continuously). The newly acquired or re-acquired paresthesia was further accompanied by increases in lacrimation and improved patient satisfaction.
Patients often reported the feeling of vibration during stimulation and tingle during stimulation pauses (for example, during off portions of waveforms having a 1 second on/1 second off pattern), and in certain cases for seconds or minutes after the stimulation had stopped after application. There were several reports of patients feeling that the vibration or the tingle moved physically along their eyelid and eyebrow, in two cases even in their nasal area (outside and/or inside the nose). Patient reception was generally very positive.
Nineteen patients had microstimulators implanted in an ocular region. (Twelve of these patients are the same patients as in Example 2.) For each patient, a patient-optimized temporally patterned waveform was determined by modulating waveform frequency, pulse width, and on/off periods while gathering patient feedback in order to maximize the reported paresthesia in the area of the orbit, as described above.
Each waveform was provided using the same controller/energizer for each patient. The waveforms tested for each patient included:
Patients were asked a series of questions for each waveform, including:
It was desirable that the patient feel sensation in the upper eyelid, since this was considered likely to correspond with activating the lacrimal and the frontal nerves in the orbit. The closer the sensation was to the eye itself and the larger the area of paresthesia, the more optimal a waveform was rated. Additionally, waveforms that were perceived as a mixture of tickle and vibration sensations in locations that corresponded with the sensory pathways of the ophthalmic branch of the trigeminal nerve (CN V1) were desirable. These locations included not only the eyelid, but also the eyebrow, the temple area of the forehead, the nose (especially the inside of the nose), and certain areas of the forehead.
For each patient, three Schirmer scores were recorded: a basal Schirmer score without any stimulation (“basal Schirmer”), an acute Schirmer score during application of a 30 Hz non-patterned waveform (“30 Hz Schirmer”), and an acute Schirmer score during application of the patient-optimized patterned waveform for each patient (“patterned Schirmer”).
Average bilateral 30 Hz Schirmer scores and average bilateral patterned Schirmer scores were both higher than average bilateral basal Schirmer scores. Average bilateral patterned Schirmer scores were higher than average bilateral 30 Hz Schirmer scores. Specific data for average bilateral Schirmer scores are shown in
More patients showed increased bilateral Schirmer scores when stimulated using the patient-optimized temporally patterned waveform than the 30 Hz non-patterned waveform. As shown in
The comparison of ipsilateral (i.e., the eye on the same side as ocular implant), contralateral (i.e., the eye opposite the ocular implant), and bilateral (i.e., the average of both eyes) Schirmer scores indicated that stimulation from a single ocular implant resulted in bilateral tear production, but the effect was more pronounced for patient-optimized temporally patterned waveform stimulation. Ipsilateral 30 Hz Schirmer scores were found to be higher than bilateral 30 Hz Schirmer scores, indicating that 30 Hz stimulation resulted in more tear production in the ipsilateral eye than the contralateral eye; and conversely, contralateral 30 Hz Schirmer scores were found to be lower than bilateral 30 Hz Schirmer scores, indicating that 30 Hz stimulation resulted in less tear production in the contralateral eye than the ipsilateral eye.
In contrast, both ipsilateral and contralateral patterned Schirmer scores were found to be similar to bilateral patterned Schirmer scores. This suggested that temporally patterned stimulation better stimulated tear production in the contralateral eye than the 30 Hz stimulation, such that the patient-optimized temporally patterned waveform was equally effective in stimulating tear production in both the ipsilateral and contralateral eyes. It was hypothesized that this was a result of the reflexive drive (activated by stimulating the lacrimal and frontal nerves) adding to the direct drive (lacrimal nerve only).
By switching frequencies, either linearly or randomly, patients experienced a mixture of vibration and tickle. By changing to the higher frequency of 70 Hz at 1 second on/1 second off, modulating the frequency (30 to 70 Hz in 5 Hz increments), and/or changing the pulse width, specific patients reported the sense of tickle in addition to vibration, tickle alone or the impression of a moving vibration, often in the combination with a moving sensation of tickle. It was also found that stimulation with a patient-optimized temporally patterned waveform allowed patients to find the location for holding the energizers/controllers in order to couple to the implant more quickly and repeatedly.
A patterned waveform was delivered to the nasal mucosa of subjects using a device as described with respect to
A rabbit was implanted with fine wire electrodes into its left frontal nerve area, and stimulation was applied at 30 Hz with amplitudes between 0.1 mA and 5.0 mA. Stimulation and baseline measurements were repeated 3 times each. As shown in Table 3 below and
This application is a divisional of U.S. patent application Ser. No. 14/920,860, filed Oct. 22, 2015, which issued as U.S. Pat. No. 9,737,712 on Aug. 22, 2017, which claims priority to U.S. Provisional Patent Application No. 62/067,416, filed on Oct. 22, 2014, and titled “STIMULATION PATTERNS,” each of which is hereby incorporated by reference herein in its entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3620219 | Barker | Nov 1971 | A |
| 3709228 | Barker et al. | Jan 1973 | A |
| 3885550 | MacLeod | May 1975 | A |
| D257495 | Bros et al. | Nov 1980 | S |
| 4495676 | Hartmetz | Jan 1985 | A |
| 4520825 | Thompson et al. | Jun 1985 | A |
| 4539988 | Shirley et al. | Sep 1985 | A |
| 4590942 | Brenman et al. | May 1986 | A |
| 4628933 | Michelson | Dec 1986 | A |
| 4681121 | Kobal | Jul 1987 | A |
| 4684362 | Holt | Aug 1987 | A |
| 4706680 | Keusch et al. | Nov 1987 | A |
| 4735207 | Nambu et al. | Apr 1988 | A |
| 4777954 | Keusch et al. | Oct 1988 | A |
| 4780932 | Bowman et al. | Nov 1988 | A |
| 4868154 | Gilbard et al. | Sep 1989 | A |
| 4926880 | Claude et al. | May 1990 | A |
| 4957480 | Morenings | Sep 1990 | A |
| 4988358 | Eppley et al. | Jan 1991 | A |
| 5025807 | Zabara | Jun 1991 | A |
| 5072724 | Marcus | Dec 1991 | A |
| 5078733 | Eveleigh et al. | Jan 1992 | A |
| 5090422 | Dahl et al. | Feb 1992 | A |
| 5099829 | Wu | Mar 1992 | A |
| 5147284 | Fedorov et al. | Sep 1992 | A |
| 5324316 | Schulman et al. | Jun 1994 | A |
| 5342410 | Braverman | Aug 1994 | A |
| 5345948 | O'Donnell, Jr. | Sep 1994 | A |
| 5360438 | Fisher | Nov 1994 | A |
| 5498681 | Askari et al. | Mar 1996 | A |
| 5514131 | Edwards et al. | May 1996 | A |
| 5533470 | Rose | Jul 1996 | A |
| 5545617 | Dartt et al. | Aug 1996 | A |
| 5571101 | Ellman et al. | Nov 1996 | A |
| 5607461 | Lathrop | Mar 1997 | A |
| 5611970 | Apollonio et al. | Mar 1997 | A |
| 5640978 | Wong | Jun 1997 | A |
| 5683436 | Mendes et al. | Nov 1997 | A |
| 5707400 | Terry et al. | Jan 1998 | A |
| 5713833 | Milligan | Feb 1998 | A |
| 5720773 | Lopez-Claros | Feb 1998 | A |
| 5733282 | Ellman et al. | Mar 1998 | A |
| 5735817 | Shantha | Apr 1998 | A |
| 5792100 | Shantha | Aug 1998 | A |
| 5794614 | Gruenke et al. | Aug 1998 | A |
| 5800685 | Perrault | Sep 1998 | A |
| 5843140 | Strojnik | Dec 1998 | A |
| 5900407 | Yerxa et al. | May 1999 | A |
| 5904658 | Niederauer et al. | May 1999 | A |
| 5948006 | Mann | Sep 1999 | A |
| 6001088 | Roberts et al. | Dec 1999 | A |
| 6020445 | Vanderlaan et al. | Feb 2000 | A |
| 6035236 | Jarding et al. | Mar 2000 | A |
| 6050999 | Paraschac et al. | Apr 2000 | A |
| 6051017 | Loeb et al. | Apr 2000 | A |
| 6083251 | Shindo | Jul 2000 | A |
| 6102847 | Stielau | Aug 2000 | A |
| 6152916 | Bige | Nov 2000 | A |
| 6205359 | Boveja | Mar 2001 | B1 |
| 6208902 | Boveja | Mar 2001 | B1 |
| 6240316 | Richmond et al. | May 2001 | B1 |
| 6246911 | Seligman | Jun 2001 | B1 |
| 6270796 | Weinstein | Aug 2001 | B1 |
| 6272382 | Faltys et al. | Aug 2001 | B1 |
| 6275737 | Mann | Aug 2001 | B1 |
| 6277855 | Yerxa | Aug 2001 | B1 |
| 6284765 | Caffrey | Sep 2001 | B1 |
| 6324429 | Shire et al. | Nov 2001 | B1 |
| 6327504 | Dolgin et al. | Dec 2001 | B1 |
| 6366814 | Boveja et al. | Apr 2002 | B1 |
| 6405079 | Ansarinia et al. | Jun 2002 | B1 |
| 6438398 | Pflugfelder et al. | Aug 2002 | B1 |
| 6458157 | Suaning | Oct 2002 | B1 |
| 6505077 | Kast et al. | Jan 2003 | B1 |
| 6526318 | Ansarinia et al. | Feb 2003 | B1 |
| 6535766 | Thompson et al. | Mar 2003 | B1 |
| 6537265 | Thanavala et al. | Mar 2003 | B2 |
| 6539253 | Thompson et al. | Mar 2003 | B2 |
| 6562036 | Ellman et al. | May 2003 | B1 |
| 6564102 | Boveja | May 2003 | B1 |
| 6578579 | Burnside et al. | Jun 2003 | B2 |
| 6604528 | Duncan | Aug 2003 | B1 |
| 6641799 | Goldberg | Nov 2003 | B2 |
| 6658301 | Loeb et al. | Dec 2003 | B2 |
| 6662052 | Sarwal et al. | Dec 2003 | B1 |
| 6684879 | Coffee et al. | Feb 2004 | B1 |
| 6701189 | Fang et al. | Mar 2004 | B2 |
| 6748951 | Schmidt | Jun 2004 | B1 |
| 6792314 | Byers et al. | Sep 2004 | B2 |
| 6829508 | Schulman et al. | Dec 2004 | B2 |
| 6853858 | Shalev | Feb 2005 | B2 |
| 6871099 | Whitehurst et al. | Mar 2005 | B1 |
| 6879859 | Boveja | Apr 2005 | B1 |
| 6885888 | Rezai | Apr 2005 | B2 |
| 6895279 | Loeb et al. | May 2005 | B2 |
| 7024241 | Bornzin et al. | Apr 2006 | B1 |
| 7054692 | Whitehurst et al. | May 2006 | B1 |
| 7067307 | Hochleitner et al. | Jun 2006 | B2 |
| 7069084 | Yee | Jun 2006 | B2 |
| 7117033 | Shalev et al. | Oct 2006 | B2 |
| 7142909 | Greenberg et al. | Nov 2006 | B2 |
| 7146209 | Gross et al. | Dec 2006 | B2 |
| 7169163 | Becker | Jan 2007 | B2 |
| 7190998 | Shalev et al. | Mar 2007 | B2 |
| 7225032 | Schmeling et al. | May 2007 | B2 |
| 7228184 | Heath | Jun 2007 | B2 |
| 7247692 | Laredo | Jul 2007 | B2 |
| 7317947 | Wahlstrand et al. | Jan 2008 | B2 |
| 7330762 | Boveja et al. | Feb 2008 | B2 |
| 7346398 | Gross et al. | Mar 2008 | B2 |
| 7369897 | Boveja et al. | May 2008 | B2 |
| 7442191 | Hovda et al. | Oct 2008 | B2 |
| 7460911 | Cosendai et al. | Dec 2008 | B2 |
| 7477947 | Pines et al. | Jan 2009 | B2 |
| 7502652 | Gaunt et al. | Mar 2009 | B2 |
| 7547447 | Yiu et al. | Jun 2009 | B2 |
| 7565204 | Matei et al. | Jul 2009 | B2 |
| 7599737 | Yomtov et al. | Oct 2009 | B2 |
| 7636597 | Gross et al. | Dec 2009 | B2 |
| 7650186 | Hastings et al. | Jan 2010 | B2 |
| D613408 | Gausmann et al. | Apr 2010 | S |
| D614303 | Gausmann et al. | Apr 2010 | S |
| D614774 | Gausmann et al. | Apr 2010 | S |
| 7725176 | Schuler et al. | May 2010 | B2 |
| 7725195 | Lima et al. | May 2010 | B2 |
| D617443 | Grenon et al. | Jun 2010 | S |
| 7758190 | Korb et al. | Jul 2010 | B2 |
| 7778703 | Gross et al. | Aug 2010 | B2 |
| 7778711 | Ben-David et al. | Aug 2010 | B2 |
| 7792591 | Rooney et al. | Sep 2010 | B2 |
| 7805200 | Kast et al. | Sep 2010 | B2 |
| 7805202 | Kuzma et al. | Sep 2010 | B2 |
| 7805203 | Ben-David et al. | Sep 2010 | B2 |
| 7809442 | Bolea et al. | Oct 2010 | B2 |
| 7835794 | Greenberg et al. | Nov 2010 | B2 |
| 7846124 | Becker | Dec 2010 | B2 |
| 7860570 | Whitehurst et al. | Dec 2010 | B2 |
| 7873421 | Karell | Jan 2011 | B2 |
| 7879079 | Tu et al. | Feb 2011 | B2 |
| D638128 | Prokop et al. | May 2011 | S |
| 7981095 | Grenon et al. | Jul 2011 | B2 |
| 7993381 | Mac et al. | Aug 2011 | B2 |
| 7998202 | Lesh | Aug 2011 | B2 |
| 8002783 | Vercellotti et al. | Aug 2011 | B2 |
| 8019419 | Panescu et al. | Sep 2011 | B1 |
| 8019441 | Wallace et al. | Sep 2011 | B2 |
| 8080047 | Yu | Dec 2011 | B2 |
| 8145322 | Yao et al. | Mar 2012 | B1 |
| 8155746 | Maltan et al. | Apr 2012 | B2 |
| 8165680 | Greenberg et al. | Apr 2012 | B2 |
| 8204591 | Ben-David et al. | Jun 2012 | B2 |
| 8231218 | Hong et al. | Jul 2012 | B2 |
| 8251983 | Larson et al. | Aug 2012 | B2 |
| 8295529 | Petersen et al. | Oct 2012 | B2 |
| 8318070 | Shiah et al. | Nov 2012 | B2 |
| D681839 | Nathanson | May 2013 | S |
| 8489189 | Tronnes | Jul 2013 | B2 |
| 8494641 | Boling et al. | Jul 2013 | B2 |
| 8626298 | Simon | Jan 2014 | B2 |
| 8676324 | Simon et al. | Mar 2014 | B2 |
| 8728136 | Feldman | May 2014 | B2 |
| 8918181 | Ackermann et al. | Dec 2014 | B2 |
| 8936594 | Wolf et al. | Jan 2015 | B2 |
| 8986301 | Wolf et al. | Mar 2015 | B2 |
| 8996137 | Ackermann et al. | Mar 2015 | B2 |
| 9079042 | Tiedtke et al. | Jul 2015 | B2 |
| 9095723 | Ackermann et al. | Aug 2015 | B2 |
| 9265956 | Ackermann et al. | Feb 2016 | B2 |
| 9440065 | Ackermann et al. | Sep 2016 | B2 |
| 9687652 | Franke et al. | Jun 2017 | B2 |
| 9717627 | Kuzma et al. | Aug 2017 | B2 |
| 9737702 | Ackermann et al. | Aug 2017 | B2 |
| 9737712 | Franke et al. | Aug 2017 | B2 |
| 9764150 | Loudin et al. | Sep 2017 | B2 |
| 9770583 | Gupta et al. | Sep 2017 | B2 |
| 9821159 | Ackermann et al. | Nov 2017 | B2 |
| 20010020177 | Gruzdowich et al. | Sep 2001 | A1 |
| 20020013594 | Dinger et al. | Jan 2002 | A1 |
| 20020035358 | Wang | Mar 2002 | A1 |
| 20020049290 | Vanderbilt et al. | Apr 2002 | A1 |
| 20020188331 | Fang et al. | Dec 2002 | A1 |
| 20030045909 | Gross et al. | Mar 2003 | A1 |
| 20030114899 | Woods et al. | Jun 2003 | A1 |
| 20030120323 | Meadows et al. | Jun 2003 | A1 |
| 20030130809 | Cohen et al. | Jul 2003 | A1 |
| 20030192784 | Zhou et al. | Oct 2003 | A1 |
| 20030233134 | Greenberg et al. | Dec 2003 | A1 |
| 20030233135 | Yee | Dec 2003 | A1 |
| 20040050392 | Tu et al. | Mar 2004 | A1 |
| 20040059466 | Block et al. | Mar 2004 | A1 |
| 20040098036 | Bergersen | May 2004 | A1 |
| 20040098067 | Ohta et al. | May 2004 | A1 |
| 20040138646 | Walla | Jul 2004 | A1 |
| 20040147973 | Hauser et al. | Jul 2004 | A1 |
| 20040151930 | Rouns et al. | Aug 2004 | A1 |
| 20040220644 | Shalev et al. | Nov 2004 | A1 |
| 20050004621 | Boveja et al. | Jan 2005 | A1 |
| 20050010250 | Schuler et al. | Jan 2005 | A1 |
| 20050010266 | Bogdanowicz | Jan 2005 | A1 |
| 20050101967 | Weber et al. | May 2005 | A1 |
| 20050101994 | Yamazaki et al. | May 2005 | A1 |
| 20050105046 | Tung | May 2005 | A1 |
| 20050137276 | Yahiaoui et al. | Jun 2005 | A1 |
| 20050159790 | Shalev et al. | Jul 2005 | A1 |
| 20050197675 | David et al. | Sep 2005 | A1 |
| 20050251061 | Schuler et al. | Nov 2005 | A1 |
| 20050267542 | David et al. | Dec 2005 | A1 |
| 20050268472 | Bourilkov et al. | Dec 2005 | A1 |
| 20060004423 | Boveja et al. | Jan 2006 | A1 |
| 20060018872 | Tew et al. | Jan 2006 | A1 |
| 20060074450 | Boveja et al. | Apr 2006 | A1 |
| 20060089673 | Schultheiss et al. | Apr 2006 | A1 |
| 20060095077 | Tronnes et al. | May 2006 | A1 |
| 20060095108 | Chowdhury et al. | May 2006 | A1 |
| 20060100668 | Ben-David et al. | May 2006 | A1 |
| 20060107958 | Sleeper | May 2006 | A1 |
| 20060142822 | Tulgar | Jun 2006 | A1 |
| 20060161225 | Sormann et al. | Jul 2006 | A1 |
| 20060195169 | Gross et al. | Aug 2006 | A1 |
| 20060206155 | Ben-David et al. | Sep 2006 | A1 |
| 20060216317 | Reinhard et al. | Sep 2006 | A1 |
| 20060235430 | Le et al. | Oct 2006 | A1 |
| 20060239482 | Hatoum et al. | Oct 2006 | A1 |
| 20060259098 | Erickson | Nov 2006 | A1 |
| 20060271024 | Gertner et al. | Nov 2006 | A1 |
| 20060271108 | Libbus et al. | Nov 2006 | A1 |
| 20070038267 | Shodo et al. | Feb 2007 | A1 |
| 20070060815 | Martin et al. | Mar 2007 | A1 |
| 20070060954 | Cameron et al. | Mar 2007 | A1 |
| 20070083245 | Lamensdorf et al. | Apr 2007 | A1 |
| 20070123938 | Haller et al. | May 2007 | A1 |
| 20070135868 | Shi et al. | Jun 2007 | A1 |
| 20070150034 | Rooney et al. | Jun 2007 | A1 |
| 20070219600 | Gertner et al. | Sep 2007 | A1 |
| 20070237797 | Peyman | Oct 2007 | A1 |
| 20070237825 | Levy et al. | Oct 2007 | A1 |
| 20070248930 | Brawn | Oct 2007 | A1 |
| 20070250119 | Tyler et al. | Oct 2007 | A1 |
| 20070250135 | Bartz-Schmidt et al. | Oct 2007 | A1 |
| 20070276314 | Becker | Nov 2007 | A1 |
| 20070276451 | Rigaux | Nov 2007 | A1 |
| 20070295327 | Bottomley | Dec 2007 | A1 |
| 20070299462 | Becker | Dec 2007 | A1 |
| 20080009897 | Duran Von Arx | Jan 2008 | A1 |
| 20080021515 | Horsager et al. | Jan 2008 | A1 |
| 20080082057 | Korb et al. | Apr 2008 | A1 |
| 20080082131 | Llanos | Apr 2008 | A1 |
| 20080109054 | Hastings et al. | May 2008 | A1 |
| 20080132933 | Gerber | Jun 2008 | A1 |
| 20080140141 | Ben-David et al. | Jun 2008 | A1 |
| 20080183242 | Tano et al. | Jul 2008 | A1 |
| 20080183243 | Shodo et al. | Jul 2008 | A1 |
| 20080208335 | Blum et al. | Aug 2008 | A1 |
| 20080269648 | Bock | Oct 2008 | A1 |
| 20080294066 | Hetling et al. | Nov 2008 | A1 |
| 20090005835 | Greenberg et al. | Jan 2009 | A1 |
| 20090012573 | Karell et al. | Jan 2009 | A1 |
| 20090018582 | Ishikawa et al. | Jan 2009 | A1 |
| 20090024187 | Erickson et al. | Jan 2009 | A1 |
| 20090024189 | Lee et al. | Jan 2009 | A1 |
| 20090043185 | McAdams et al. | Feb 2009 | A1 |
| 20090056709 | Worsoff | Mar 2009 | A1 |
| 20090099600 | Moore et al. | Apr 2009 | A1 |
| 20090099623 | Bentwich et al. | Apr 2009 | A1 |
| 20090099626 | de Juan, Jr. et al. | Apr 2009 | A1 |
| 20090101139 | Karell | Apr 2009 | A1 |
| 20090124965 | Greenberg et al. | May 2009 | A1 |
| 20090138061 | Stephens et al. | May 2009 | A1 |
| 20090156581 | Dillon et al. | Jun 2009 | A1 |
| 20090157142 | Cauller et al. | Jun 2009 | A1 |
| 20090157145 | Cauller | Jun 2009 | A1 |
| 20090157147 | Cauller et al. | Jun 2009 | A1 |
| 20090192571 | Stett et al. | Jul 2009 | A1 |
| 20090204142 | Becker | Aug 2009 | A1 |
| 20090241840 | Mills | Oct 2009 | A1 |
| 20090264966 | Blum et al. | Oct 2009 | A1 |
| 20090281594 | King et al. | Nov 2009 | A1 |
| 20090281596 | King et al. | Nov 2009 | A1 |
| 20090299418 | Shalev et al. | Dec 2009 | A1 |
| 20090306738 | Weiss et al. | Dec 2009 | A1 |
| 20100030150 | Paques et al. | Feb 2010 | A1 |
| 20100076423 | Muller | Mar 2010 | A1 |
| 20100087896 | McCreery | Apr 2010 | A1 |
| 20100094280 | Muller | Apr 2010 | A1 |
| 20100139002 | Walker et al. | Jun 2010 | A1 |
| 20100152708 | Li et al. | Jun 2010 | A1 |
| 20100161004 | Najafi et al. | Jun 2010 | A1 |
| 20100168513 | Pless et al. | Jul 2010 | A1 |
| 20100179468 | Becker | Jul 2010 | A1 |
| 20100211132 | Nimmagadda et al. | Aug 2010 | A1 |
| 20100241195 | Meadows et al. | Sep 2010 | A1 |
| 20100274164 | Juto | Oct 2010 | A1 |
| 20100274224 | Jain et al. | Oct 2010 | A1 |
| 20100274313 | Boling et al. | Oct 2010 | A1 |
| 20100280509 | Muller et al. | Nov 2010 | A1 |
| 20100288275 | Djupesland et al. | Nov 2010 | A1 |
| 20100318159 | Aghassian et al. | Dec 2010 | A1 |
| 20110021975 | Covello | Jan 2011 | A1 |
| 20110028807 | Abreu | Feb 2011 | A1 |
| 20110028883 | Juan, Jr. et al. | Feb 2011 | A1 |
| 20110077551 | Videbaek | Mar 2011 | A1 |
| 20110077698 | Tsampazis et al. | Mar 2011 | A1 |
| 20110093043 | Torgerson et al. | Apr 2011 | A1 |
| 20110151393 | Frey, II et al. | Jun 2011 | A1 |
| 20110152969 | Zehnder et al. | Jun 2011 | A1 |
| 20110202121 | Wen | Aug 2011 | A1 |
| 20110218590 | Degiorgio et al. | Sep 2011 | A1 |
| 20110234971 | Yeh | Sep 2011 | A1 |
| 20110275734 | Scales et al. | Nov 2011 | A1 |
| 20110276107 | Simon et al. | Nov 2011 | A1 |
| 20110282251 | Baker et al. | Nov 2011 | A1 |
| 20110295336 | Sharma et al. | Dec 2011 | A1 |
| 20110313330 | Loushin et al. | Dec 2011 | A1 |
| 20110313481 | De Vos | Dec 2011 | A1 |
| 20120053648 | Neher et al. | Mar 2012 | A1 |
| 20120130398 | Ackermann et al. | May 2012 | A1 |
| 20120197338 | Su et al. | Aug 2012 | A1 |
| 20120232615 | Barolat et al. | Sep 2012 | A1 |
| 20120232618 | Feldman | Sep 2012 | A1 |
| 20120234332 | Shantha | Sep 2012 | A1 |
| 20120253249 | Wilson et al. | Oct 2012 | A1 |
| 20120298105 | Osorio et al. | Nov 2012 | A1 |
| 20120315329 | Ahn et al. | Dec 2012 | A1 |
| 20120316557 | Sartor et al. | Dec 2012 | A1 |
| 20120323214 | Shantha | Dec 2012 | A1 |
| 20120323227 | Wolf et al. | Dec 2012 | A1 |
| 20120323232 | Wolf et al. | Dec 2012 | A1 |
| 20120330376 | Flynn et al. | Dec 2012 | A1 |
| 20130006095 | Jenkins et al. | Jan 2013 | A1 |
| 20130006326 | Ackermann et al. | Jan 2013 | A1 |
| 20130053733 | Korb et al. | Feb 2013 | A1 |
| 20130053737 | Scerbo | Feb 2013 | A1 |
| 20130065765 | Selifonov et al. | Mar 2013 | A1 |
| 20130158451 | Juto et al. | Jun 2013 | A1 |
| 20130158626 | DeGiorgio et al. | Jun 2013 | A1 |
| 20130172790 | Badawi | Jul 2013 | A1 |
| 20130178937 | Vassallo et al. | Jul 2013 | A1 |
| 20130253387 | Bonutti et al. | Sep 2013 | A1 |
| 20130261706 | Mirro et al. | Oct 2013 | A1 |
| 20130270491 | Park et al. | Oct 2013 | A1 |
| 20130274831 | Otto et al. | Oct 2013 | A1 |
| 20130304154 | Goodman et al. | Nov 2013 | A1 |
| 20130310887 | Curtis | Nov 2013 | A1 |
| 20140012182 | Shantha et al. | Jan 2014 | A1 |
| 20140081353 | Cook et al. | Mar 2014 | A1 |
| 20140088463 | Wolf et al. | Mar 2014 | A1 |
| 20140163580 | Tischendorf et al. | Jun 2014 | A1 |
| 20140214120 | Simon et al. | Jul 2014 | A1 |
| 20140257205 | Schaller | Sep 2014 | A1 |
| 20140257433 | Ackermann et al. | Sep 2014 | A1 |
| 20140277429 | Kuzma et al. | Sep 2014 | A1 |
| 20140316310 | Ackermann et al. | Oct 2014 | A1 |
| 20140316396 | Wolf et al. | Oct 2014 | A1 |
| 20140316485 | Ackermann et al. | Oct 2014 | A1 |
| 20140362339 | Imafuku | Dec 2014 | A1 |
| 20140371565 | Glasser | Dec 2014 | A1 |
| 20140371812 | Ackermann et al. | Dec 2014 | A1 |
| 20150088156 | Ackermann et al. | Mar 2015 | A1 |
| 20150238754 | Loudin et al. | Aug 2015 | A1 |
| 20150335900 | Ackermann et al. | Nov 2015 | A1 |
| 20150362755 | Lee et al. | Dec 2015 | A1 |
| 20160114163 | Franke et al. | Apr 2016 | A1 |
| 20160114172 | Loudin et al. | Apr 2016 | A1 |
| 20160158548 | Ackermann et al. | Jun 2016 | A1 |
| 20160270656 | Samec et al. | Sep 2016 | A1 |
| 20160367795 | Ackermann et al. | Dec 2016 | A1 |
| 20160367806 | Kahook | Dec 2016 | A1 |
| 20170049619 | Kahook | Feb 2017 | A1 |
| 20170157401 | Loudin et al. | Jun 2017 | A1 |
| 20170239459 | Loudin et al. | Aug 2017 | A1 |
| 20170252563 | Franke et al. | Sep 2017 | A1 |
| 20170312521 | Franke et al. | Nov 2017 | A1 |
| 20170340884 | Franke et al. | Nov 2017 | A1 |
| 20170354536 | Kuzma et al. | Dec 2017 | A1 |
| 20170368332 | Ackermann et al. | Dec 2017 | A1 |
| 20170368359 | Loudin et al. | Dec 2017 | A1 |
| 20180064940 | Ackermann et al. | Mar 2018 | A1 |
| 20180064941 | Ackermann et al. | Mar 2018 | A1 |
| 20180064942 | Ackermann et al. | Mar 2018 | A1 |
| Number | Date | Country |
|---|---|---|
| 101939043 | Jan 2011 | CN |
| 103467652 | Dec 2013 | CN |
| 2102681-0001 | Oct 2012 | EM |
| 2199000-0001 | Mar 2013 | EM |
| 0 109 935 | May 1984 | EP |
| 1 497 483 | Jan 2005 | EP |
| 1 651 307 | May 2006 | EP |
| 1 919 553 | May 2008 | EP |
| 1 958 661 | Aug 2008 | EP |
| 2 205 193 | Jul 2010 | EP |
| 2 205 314 | Jul 2010 | EP |
| 2 129 690 | Mar 1987 | GB |
| 2 456 002 | Jul 2009 | GB |
| 2002-325851 | Nov 2002 | JP |
| 2002-539859 | Nov 2002 | JP |
| 2005-052461 | Mar 2005 | JP |
| 2006-515900 | Jun 2006 | JP |
| 2007-044323 | Feb 2007 | JP |
| 2007-528751 | Oct 2007 | JP |
| 2008-183248 | Aug 2008 | JP |
| 2008-541850 | Nov 2008 | JP |
| 2010-505563 | Feb 2010 | JP |
| 2010-051562 | Mar 2010 | JP |
| 2010-537777 | Dec 2010 | JP |
| 2011-030734 | Feb 2011 | JP |
| WO-0056393 | Sep 2000 | WO |
| WO-0062672 | Oct 2000 | WO |
| WO-2003087433 | Oct 2003 | WO |
| WO-2004026106 | Apr 2004 | WO |
| WO-2004026106 | Apr 2004 | WO |
| WO-2004043217 | May 2004 | WO |
| WO-2004043217 | May 2004 | WO |
| WO-2004091453 | Oct 2004 | WO |
| WO-2004112893 | Dec 2004 | WO |
| WO-2004112893 | Dec 2004 | WO |
| WO-2005007234 | Jan 2005 | WO |
| WO-2005007234 | Jan 2005 | WO |
| WO-2005030025 | Apr 2005 | WO |
| WO-2005030025 | Apr 2005 | WO |
| WO-2005060984 | Jul 2005 | WO |
| WO-2006127366 | Nov 2006 | WO |
| WO-2008156501 | Dec 2008 | WO |
| WO-2008156501 | Dec 2008 | WO |
| WO-2009035571 | Mar 2009 | WO |
| WO-2009035571 | Mar 2009 | WO |
| WO-2009048580 | Apr 2009 | WO |
| WO-2009070709 | Jun 2009 | WO |
| WO-2010003011 | Jan 2010 | WO |
| WO-2010027743 | Mar 2010 | WO |
| WO-2010099818 | Sep 2010 | WO |
| WO-2011011373 | Jan 2011 | WO |
| WO-2012068247 | May 2012 | WO |
| WO-2012139063 | Oct 2012 | WO |
| WO-2012139063 | Oct 2012 | WO |
| WO-2013055940 | Apr 2013 | WO |
| WO-2013055940 | Apr 2013 | WO |
| WO-2013157320 | Oct 2013 | WO |
| WO-2013165697 | Nov 2013 | WO |
| WO-2013166353 | Nov 2013 | WO |
| WO-2014138709 | Sep 2014 | WO |
| WO-2014165124 | Oct 2014 | WO |
| WO-2014172693 | Oct 2014 | WO |
| WO-2014172693 | Oct 2014 | WO |
| WO-2015130707 | Sep 2015 | WO |
| WO-2015130707 | Sep 2015 | WO |
| WO-2016015025 | Jan 2016 | WO |
| WO-2016065211 | Apr 2016 | WO |
| WO-2016065213 | Apr 2016 | WO |
| WO-2016065215 | Apr 2016 | WO |
| Entry |
|---|
| Acar, M. et al. (2013). “Ocular surface assessment in patients with obstructive sleep apnea-hypopnea syndrome,” Sleep Breath 17(2):583-588. |
| Amparo (2013). “Topical Interleukin 1 Receptor Antagonist for Treatment of Dry Eye Disease,” JAMA Ophth. 131(6):E1-E9. |
| Anonymous (2007). “The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007),” Ocul. Surf. 5(2):93-107. |
| Bajpai et al. (2012). “Preparation, Characterization and Water Uptake Behavior of Polysaccharide Based Nanoparticles,” Prog. Nanotech. Nanomat. 1(1):9-17. |
| Baraniuk et al. (2007). “Nasonasal Reflexes, the Nasal Cycle, and Sneeze,” Curr. Allergy and Asthma Reports 7:105-111. |
| Baroody FM, Foster KA, Markaryan A, et al. Nasal ocular reflexes and eye symptoms in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2008;100:194-199. |
| Baroody FM, Shenaq D, DeTineo M, et al. Fluticasone furoate nasal spray reduces the nasal-ocular reflex: a mechanism for the efficacy of topical steroids in controlling allergic eye symptoms. J Allergy Clin Immunol 2009;123:1342-1348. |
| Boberg-Ans J. (1955). “Experience in clinical examination of corneal sensitivity: corneal sensitivity and the naso-lacrimal reflex after retrobulbar anaesthesia,” Br. J. Ophthalmol. 39(12):705-726. |
| Calonge (2001). “The Treatment of Dry Eye,” Survey Ophth. 45(2):S227-S239. |
| Cipriano et al. (2014). “Superabsorbent Hydrogels That Are Robust and Highly Stretchable,” Am. Chem Soc. 47(13):4445-4452. |
| Corrected Notice of Allowance dated Feb. 23, 2015, for U.S. Appl. No. 14/256,915, filed Apr. 18, 2014, 2 pages. |
| Corrected Notice of Allowance dated Jun. 9, 2017, for U.S. Appl. No. 14/920,860, filed Oct. 22, 2015, 2 pages. |
| Dart et al. (2002). “Effects of 25% Propylene Glycol Hydrogel (Solugel) on Second Intention Wound Healing in Horses,” Vet. Surg. 31(4):309-313. |
| Drummond PD. Lacrimation and cutaneous vasodilatation in the face induced by painful stimulation of the nasal ala and upper lip. J Auton Nerv Syst 1995;51:109-16. |
| Elsby et al. (1967). “Lacrimal Secretion in the Cat,” Br. J. Pharm. Chemother. 29(1):1-7. |
| Extended European Search Report dated Nov. 18, 2016, for EP Application No. 14 785 631.4, filed on Apr. 18, 2014, 7 pages. |
| Extended European Search Report received for European Patent Application No. 11842076.9, dated Oct. 10, 2014, 5 pages. |
| Extended European Search Report received for European Patent Application No. 12768458.7, dated Aug. 28, 2014, 7 pages. |
| Extended European Search Report dated Oct. 21, 2016, for EP Application No. 14 778 719.6, filed on Mar. 12, 2014, 8 pages. |
| Final Office Action for U.S. Appl. No. 13/441,806, dated Mar. 12, 2015, 10 pages. |
| Final Office Action for U.S. Appl. No. 13/441,806, dated May 20, 2016, 10 pages. |
| Final Office Action for U.S. Appl. No. 14/816,846, dated May 11, 2016, 12 pages. |
| Final Office Action received for U.S. Appl. No. 14/207,072, dated Jun. 22, 2016. |
| Final Office Action dated Mar. 10, 2017, for U.S. Appl. No. 14/920,847, filed Oct. 22, 2015, 12 pages. |
| Final Office Action dated May 17, 2017, for U.S. Appl. No. 13/441,806, filed Apr. 6, 2012, 5 pages. |
| Final Office Action for U.S. Appl. No. 14/256,916, dated Apr. 8, 2015, 16 pages. |
| Final Office Action for U.S. Appl. No. 14/313,937 dated Apr. 29, 2015, 13 pages. |
| Final Office Action for U.S. Appl. No. 14/630,471, dated Sep. 26, 2016, 22 pages. |
| Final Office Action for U.S. Appl. No. 14/256,916, dated Aug. 19, 2016, 19 pages. |
| Final Office Action dated Sep. 23, 2016, for U.S. Appl. No. 14/809,109, filed Jul. 24, 2015, 10 pages. |
| Final Office Action dated Feb. 1, 2017, for U.S. Appl. No. 14/920,852, filed Oct. 22, 2015, 20 pages. |
| Fujisawa et al. (2002). “The Effect of Nasal Mucosal Stimulation on Schirmer Tests in Sjogren's Syndrome and Dry Eye Patients.” Lac. Gland Tear Film Dry Eye Syndrome 3 506:1221-1226. |
| Gupta et al. (1997). “Nasolacrimal Stimulation of Aqueous Tear Production,” Cornea 16(6):645-648. |
| Heigle TJ, Pflugfelder SC. Aqueous tear production in patients with neurotrophic keratitis. Cornea 1996;15:135-8. |
| Holzer P. Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol Rev 1991;43:143-201. |
| Ikemura et al. (2008). “UV-VIS Spectra and Photoinitiation Behaviors of Acylphosphine Oxide and Bisacylphosphine Oxide Derivatives in unfilled, Light-Cured Dental Resins,” Dent. Mat. J. 27:765-774. |
| International Search Report & Written Opinion received for PCT Patent Application No. PCT/US2011/060989, dated Feb. 23, 2012, 16 pages. |
| International Search Report & Written Opinion received for PCT Patent Application No. PCT/US2014/022158, dated Jul. 30, 2014, 8 pages. |
| International Search Report and Written Opinion received for PCT Application No. PCT/US2015/042130, dated Oct. 28, 2015, 5 pages. |
| International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2014/034733, dated Dec. 5, 2014, 12 pages. |
| International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2015/017379, dated Jul. 24, 2015, 19 pages. |
| International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2015/057023. dated Mar. 4, 2016. 10 pages. |
| International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2014/024496, dated Aug. 22, 2014, 11 pages. |
| International Search Report received for PCT Patent Application No. PCT/US2012/32629, dated Oct. 26, 2012, 4 pages. |
| International Search Report dated Feb. 10, 2016, for PCT Patent Application No. PCT/US2015/57021, filed on Oct. 22, 2015, 4 pages. |
| International Search Report received for PCT Patent Application No. PCT/US2015/57019, dated Feb. 11, 2016, 4 pages. |
| Krupin T, Cross DA, Becker B. Decreased basal tear production associated with general anesthesia. Arch Ophthalmol 1977;95:107-108. |
| Lora et al. (2009). “Lacrimal Nerve Stimulation by a Neurostimulator for Tear Production,” Invest. Ophth. Vis. Science 50(13):172. |
| Loth S, Bende M. Effect of nasal anaesthesia on lacrimal function after nasal allergen challenge. Clin Exp Allergy 1994;24:375-376. |
| Meng, I.D. et al. (2013). “The role of corneal afferent neurons in regulating tears under normal and dry eye conditions,” Exp. Eye Res. 117:79-87. |
| Mallepally et al. (2013). “Superabsorbent Alginate Aerogels,” J. Supercritical Fluids 79:1-5. |
| Non Final Office Action received for U.S. Appl. No. 13/441,806, dated Sep. 17, 2015, 11 pages. |
| Non-Final Office Action received for U.S. Appl. No. 13/298,042, dated Oct. 2, 2013, 10 pages. |
| Non-Final Office Action received for U.S. Appl. No. 13/441,806, dated Dec. 18, 2013, 9 pages. |
| Non-Final Office Action received for U.S. Appl. No. 14/201,753, dated Apr. 2, 2015, 6 pages. |
| Non-Final Office Action received for U.S. Appl. No. 14/816,846, dated Sep. 11, 2015, 5 pages. |
| Non Final Office Action received for U.S. Appl. No. 14/207,072, dated Dec. 9, 2015. |
| Non-Final Office Action dated Sep. 27, 2016, for U.S. Appl. No. 14/920,847, filed Oct. 22, 2015, 13 pages. |
| Non-Final Office Action dated Nov. 2, 2016, for U.S. Appl. No. 13/441,806, filed Apr. 6, 2012, 10pages. |
| Non-Final Office Action dated Dec. 6, 2016, for U.S. Appl. No. 14/816,846, filed Aug. 3, 2015, 13 pages. |
| Non-Final Office Action dated Jul. 17, 2017, for U.S. Appl. No. 15/598,063, filed May 17, 2017, 9 pages. |
| Non-Final Office Action received for U.S. Appl. No. 14/256,915, dated Aug. 13, 2014, 11 pages. |
| Non-Final Office Action received for U.S. Appl. No. 14/256,916, dated Sep. 12, 2014, 24 pages. |
| Non-Final Office Action received for U.S. Appl. No. 14/313,937, dated Nov. 19, 2014, 12 pages. |
| Non-Final Office Action dated Jun. 14, 2016, for U.S. Appl. No. 14/630,471, filed Feb. 24, 2015, 24 pages. |
| Non-Final Office Action received for U.S. Appl. No. 14/809,109, dated Apr. 8, 2016, 8 pages. |
| Non-Final Office Action Received for U.S. Appl. No. 14/920,860, dated Aug. 17, 2016, 11 pages. |
| Non-Final Office Action received for U.S. Appl. No. 14/256,916, dated Nov. 19, 2015, 20 pages. |
| Non-Final Office Action Received for U.S. Appl. No. 14/313,937, dated Oct. 6, 2015, 7 pages. |
| Non-Final Office Action Received for U.S. Appl. No. 14/920,852, dated Aug. 1, 2016, 20 pages. |
| Non-Final Office Action dated Sep. 30, 2016, for U.S. Appl. No. 15/256,392, filed Sep. 2, 2016, 14 pages. |
| Non-Final Office Action dated Feb. 14, 2017, for U.S. Appl. No. 14/630,471, filed Feb. 24, 2015, 23 pages. |
| Non-Final Office Action dated Apr. 19, 2017, for U.S. Appl. No. 14/256,916, filed Apr. 18, 2014, 19 pages. |
| Non-Final Office Action dated Jul. 31, 2017, for U.S. Appl. No. 14/920,852, filed Oct. 22, 2015, 18 pages. |
| Notice of Allowance received for U.S. Appl. No. 14/201,753, dated Dec. 15, 2015, 2 pages. |
| Notice of Allowance received for U.S. Appl. No. 14/201,753, dated Oct. 15, 2015, 5 pages. |
| Notice of Allowance received for U.S. Appl. No. 13/298,042, dated Apr. 29, 2014, 5 pages. |
| Notice of Allowance received for U.S. Appl. No. 13/298,042, dated Aug. 11, 2014, 7 pages. |
| Notice of Allowance received for U.S. Appl. No. 13/298,042, dated Nov. 13, 2014, 5 pages. |
| Notice of Allowance received for U.S. Appl. No. 14/561,107, dated Mar. 31, 2015, 7 pages. |
| Notice of Allowance received for U.S. Appl. No. 14/256,915, dated Nov. 26, 2014, 7 pages. |
| Notice of Allowance received for U.S. Appl. No. 14/313,937, dated Feb. 19, 2016, 8 pages. |
| Notice of Allowance received for U.S. Appl. No. 14/313,937, dated May 2, 2016, 7 pages. |
| Notice of Allowability dated Dec. 19, 2016, for U.S. Appl. No. 14/809,109, filed Jul. 24, 2015, 8 pages. |
| Notice of Allowance dated Jan. 19, 2017, for U.S. Appl. No. 14/920,860, filed Oct. 22, 2015, 5 pages. |
| Notice of Allowance dated Mar. 21, 2017, for U.S. Appl. No. 14/809,109, filed Jul. 24, 2015, 8 pages. |
| Notice of Allowance dated Mar. 28, 2017, for U.S. Appl. No. 14/207,072, filed Mar. 12, 2014, 8 pages. |
| Notice of Allowance dated May 30, 2017, for U.S. Appl. No. 14/920,847, filed Oct. 22, 2015, 5 pages. |
| Notice of Allowance dated Apr. 17, 2017, for U.S. Appl. No. 15/256,392, filed Sep. 2, 2016, 10 pages. |
| Notice of Allowance dated Apr. 20, 2017, for U.S. Appl. No. 14/920,860, filed Oct. 22, 2015, 5 pages. |
| Notice of Allowance dated May 26, 2017, for U.S. Appl. No. 14/630,471, filed Feb. 24, 2015, 5 pages. |
| Notice of Allowance dated Aug. 2, 2017, for U.S. Appl. No. 13/441,806, filed Apr. 6, 2012, 5 pages. |
| Pasqui et al. (2012). “Polysaccharide-Based Hydrogels: The Key Role of Water in Affecting Mechanical Properties,” Polymers 4(3):1517-1534. |
| Philip G, Baroody FM, Proud D, et al. The human nasal response to capsaicin. J Allergy Clin Immunol 1994;94:1035-1045. |
| Roessler et al. (2009). “Implantation and Explantation of a Wireless Epiretinal Retina Implant Device: Observations During the EPIRET3 Prospective Clinical Trial,” Invest. Ophthal. Visual Science 50(6):3003-3008. |
| Ruskell (2004). “Distribution of Pterygopalatine Ganglion Efferents to the Lacrimal Gland in Man,” Exp. Eye Res. 78(3):329-335. |
| Sall et al. (2000). “Two Multicenter, Randomized Studies of the Efficacy and Safety of Cyclosporine Ophthalmic Emulsion in Moderate to Severe Dry Eye Disease,” Ophth. 107(4):631-639. |
| Shaari et al. (1995). “Rhinorrhea is decreased in dogs after nasal application of botulinum toxin,” Oto. Head Neck Surg. 112(4):566-571. |
| Stjernschantz et al. (1979). “Electrical Stimulation of the Fifth Cranial Nerve in Rabbits: Effects on Ocular Blood Flow, Extravascular Albumin Content and Intraocular Pressure,” Exp. Eye Res. 28(2):229-238. |
| Stjernschantz et al. (1980). “Vasomotor effects of Facial Nerve Stimulation: Noncholinergic Vasodilation in the eye,” Acta Phys. Scand. 109(1):45-50. |
| Tsubota (1991). “The Importance of the Schirmer Test with Nasal Stimulation,” Am. J. Ophth. 111:106-108. |
| Velikay-Parel et al. (2011). “Perceptual Threshold and Neuronal Excitability as Long-Term Safety Evaluation in Retinal Implants,” Invest. Opht. Visual Science E-Abstract 2590, 2 pages. |
| Written Opinion received for PCT Patent Application No. PCT/US2015/57021, dated Feb. 10, 2016, 5 pages. |
| Written Opinion received for PCT Patent Application No. PCT/US2012/032629, dated Oct. 26, 2012, 8 pages. |
| Written Opinion received for PCT Patent Application No. PCT/US2015/57019, dated Feb. 11, 2016, 6 pages. |
| Zilstorff-Pedersen (1965). “Quantitative Measurements of the Nasolacrimal Reflex,” Arch. Oto. 81:457-462. |
| Corrected Notice of Allowance dated Jul. 17, 2017, for U.S. Appl. No. 15/256,392, filed Sep. 2, 2016. 2 pages. |
| Extended European Search Report dated Nov. 27, 2017, for EP Application No. 17 167 504.4, filed on Apr. 6, 2012, 9 pages. |
| Extended European Search Report dated Sep. 19, 2017, for EP Application No. 15 754 827.2, filed on Feb. 24, 2015, 9 pages. |
| Extended European Search Report dated Jan. 8, 2018, for EP Application No. 15 824 539.9, filed on Jul. 24, 2015, 6 pages. |
| Final Office Action dated Sep. 1, 2017, for U.S. Appl. No. 14/816,846, filed Aug. 3, 2015, 12 pages. |
| Final Office Action dated Nov. 8, 2017, for U.S. Appl. No. 14/256,916, filed Apr. 18, 2014, 21 pages. |
| Final Office Action dated Dec. 20, 2017, for U.S. Appl. No. 14/920,852, filed Oct. 22, 2015, 18 pages. |
| Final Office Action dated Feb. 22, 2018, for U.S. Appl. No. 14/256,916, filed Apr. 18, 2014, 24 pages. |
| Eye Health (2014). “Watery eyes in cold weather,” Oregon Eye Specialists, PC, located at http://www.oregoneyes.net/watery-eyes-in-cold-weather/, 4 total pages. |
| Friedman et al. (2016). “A nonrandomized, open-label study to evaluate the effect of nasal stimulation on tear production in subjects with dry eye disease,” Clin. Ophthal. 10:795-804. |
| Galor, A. et al. (2014). “Environmental factors affect the risk of dry eye syndrome in a United States veteran population,” Opth. 121:972-973. |
| Harvard Health Publishing (2010). “Dry eyes and what you can try,” Harvard Medical School, 2 total pages. |
| International Search Report dated Aug. 7, 2017, for PCT Patent Application No. PCT/US2017/30617, filed on May 2, 2017, 2 pages. |
| International Search Report dated Feb. 12, 2018, for PCT Patent Application No. PCT/US2017/63916, filed on Nov. 30, 2017, 3 pages. |
| Notice of Allowance dated Jan. 29, 2018, for U.S. Appl. No. 15/700,935, filed Sep. 11, 2017, 7 pages. |
| Notice of Allowance dated Feb. 13, 2018, for U.S. Appl. No. 15/700,935, filed Sep. 11, 2017, 2 pages. |
| Petrov, A. et al. (2016). “SkQ1 Ophthalmic Solution for Dry Eye Treatment: Results of a Phase 2 Safety and Efficacy Clinical Study in the Environment and During Challenge in the Controlled Adverse Environment Model,” Adv. Ther. 33:96-115. |
| Vapor Pressure Data for H2O (2012). Handbook of Chemistry and Physics, 73rd edition, 1 total page. |
| van Setten, G. et al. (2016). “Evidence of seasonality and effects of psychrometry in dry eye disease,” Acta Opth. 94:499-506. |
| Written Opinion of the International Search Authority dated Aug. 7, 2017, for PCT Patent Application No. PCT/US2017/30617, filed on May 2, 2017, 4 pages. |
| Written Opinion of the International Searching Authority dated Feb. 12, 2018, for PCT Patent Application No. PCT/US2017/63916, filed on Nov. 30, 2017, 6 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20170340884 A1 | Nov 2017 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62067416 | Oct 2014 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 14920860 | Oct 2015 | US |
| Child | 15676910 | US |
